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With Biologically Distinct Properties
Abstract
Viruses are obligate, intracellular pathogens that hijack host cell machinery to replicate. Innate immunity
is the first line of defense against such perceived threats through recognition of broadly conserved
pathogen signatures. Tetherin (also known as BST2/CD317/HM1.24) is an innate immune factor that
senses and restricts egress, the final step of viral replication. Tetherin potently reduces cell-free virus
spread by indiscriminately “tethering” particles at the cell surface via direct anchoring to the host
membrane. The majority of previous studies on Tetherin focused on elucidating the minimal structural
features necessary for tethering viral particles and understanding how viruses counter Tetherin function.
While the cytoplasmic tail of Tetherin is dispensable for restricting virus release in the absence of certain
viral antagonists, our work, in part, has focused on conserved residues within the tail, hypothesizing these
conserved features could provide insight into previously under-studied biology, including a poorly
characterized signaling function. In Chapter 2 we show that human Tetherin can exist as two alternatively
translated isoforms [long (l-) and short (s-)]. s-Tetherin lacks the first 12 amino acids, a difference that
confers functional differences. We found s-Tetherin to be exquisitely resistant to downregulation by the
best characterized Tetherin antagonist, HIV-1 Vpu. l-Tetherin, which is sensitive to Vpu, was shown to be a
potent activator of NF-κB. A dual-tyrosine motif, unique to l-Tetherin, was identified as an important
determinant. In Chapter 3 we describe additional determinants of signaling. Interestingly, we identified
compensatory mutations that produce a tyrosine-independent signaling-competent Tetherin called SY. We
demonstrate that SY Tetherin utilizes a similar signaling pathway as wt Tetherin. We believe this mutant,
at the very least, can be used as a tool to further elucidate how Tetherin engages signaling machinery.
Moreover, the identified compensatory changes in the cytoplasmic tail may be useful in exploring what we
hypothesize to be a previously uncharacterized regulatory motif. In this dissertation, we explored two
novel aspects of Tetherin biology. Our understanding of how Tetherin isoform expression and Tetherinmediated signaling is regulated could provide mechanisms by which we can target and enhance immune
responses during infection by clinically relevant viruses.
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PREFACE
I have always been fascinated with understanding why things exist as they are. Because
of this curiosity, my two favorite subjects in high school were history and biology. History taught
me about the events of the past and how WE as society have been shaped in the present. War
has been at the center of shaping the world, as we know it today. Countless lives sacrificed and
an innumerable amount of damage both directed and collateral; long-lasting memories ingrained
in the minds of the survivors with the hope that we learn from the past to progress as a society,
moving forward toward a better future.
Biology peaked my interest because of my curiosity of how WE, as individuals, function.
War between men has shaped the world we live in, but what I found even more remarkable and
fascinating, is that microscopic wars are constantly being waged within men, with many aspects
paralleling what we see on actual battlefields. The continual struggle between host and pathogen
peaked my interest in infectious disease. The inner workings of the immune system and its
molecular “arms race” with pathogens have provided insight into our evolutionary history.
Lessons learned from this basic biology has been instrumental in developing treatments to some
of the most debilitating and deadly maladies, tipping the fulcrum in OUR, the hosts’, favor.
However, pathogens evolve and find a way to evade host responses. There is a lot of evidence of
host-pathogen co-evolution, though molecular détente is typically not an immediate option,
The following work delves into understanding an innate immune factor encoded by our
cells as part of its arsenal to battle viral infection. This dissertation sought to elucidate previously
understudied biology of the antiviral factor, Tetherin. Our work has shed light to a previously
uncharacterized signaling function, which has bettered our understanding of host-pathogen
interactions. I am thankful for being afforded the opportunity to pursue this work and to develop it
as my own. Even through the ups and downs, the experience has been extremely enriching and
humbling. Many thanks again, to those involved directly and indirectly, for allowing this work to
move forward.
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ABSTRACT

INSIGHT INTO TETHERIN-MEDIATED SIGNALING VIA THE DISCOVERY OF A NOVEL
ISOFORM WITH BIOLOGICALLY DISTINCT PROPERTIES

Luis J. Cocka
Paul Bates

Viruses are obligate, intracellular pathogens that hijack host cell machinery to replicate. Innate
immunity is the first line of defense against such perceived threats through recognition of broadly
conserved pathogen signatures. Tetherin (also known as BST2/CD317/HM1.24) is an innate
immune factor that senses and restricts egress, the final step of viral replication. Tetherin potently
reduces cell-free virus spread by indiscriminately “tethering” particles at the cell surface via direct
anchoring to the host membrane. The majority of previous studies on Tetherin focused on
elucidating the minimal structural features necessary for tethering viral particles and
understanding how viruses counter Tetherin function. While the cytoplasmic tail of Tetherin is
dispensable for restricting virus release in the absence of certain viral antagonists, our work, in
part, has focused on conserved residues within the tail, hypothesizing these conserved features
could provide insight into previously under-studied biology, including a poorly characterized
signaling function. In Chapter 2 we show that human Tetherin can exist as two alternatively
translated isoforms [long (l-) and short (s-)]. s-Tetherin lacks the first 12 amino acids, a difference
that confers functional differences. We found s-Tetherin to be exquisitely resistant to
downregulation by the best characterized Tetherin antagonist, HIV-1 Vpu. l-Tetherin, which is
sensitive to Vpu, was shown to be a potent activator of NF-κB. A dual-tyrosine motif, unique to lTetherin, was identified as an important determinant. In Chapter 3 we describe additional
determinants of signaling. Interestingly, we identified compensatory mutations that produce a
tyrosine-independent signaling-competent Tetherin called SY. We demonstrate that SY Tetherin
xii

utilizes a similar signaling pathway as wt Tetherin. We believe this mutant, at the very least, can
be used as a tool to further elucidate how Tetherin engages signaling machinery. Moreover, the
identified compensatory changes in the cytoplasmic tail may be useful in exploring what we
hypothesize to be a previously uncharacterized regulatory motif. In this dissertation, we explored
two novel aspects of Tetherin biology. Our understanding of how Tetherin isoform expression and
Tetherin-mediated signaling is regulated could provide mechanisms by which we can target and
enhance immune responses during infection by clinically relevant viruses.
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CHAPTER 1: INTRODUCTION TO TETHERIN – AN INTRINSIC RESTRICTION
FACTOR AND IMMUNE SENSOR OF ENVELOPED VIRUS EGRESS

“All delays are dangerous in war.” – John Dryden

General Overview of Innate Immune Responses to Viral Infection
Viral sensing by intrinsic immune receptors
Viruses are highly abundant pathogens in nature that can present a burden to every living
organism from unicellular bacteria to multicellular plants and animals. Though not considered
technically alive, viruses share some properties with living things to ensure species survival,
including genome maintenance across generations and an ability to adapt to the environment.
Viral replication is contingent on infecting a host cell. However, cells express immune barriers that
can block essentially every stage of viral replication. This selective pressure, coupled with errorprone replication machinery, particularly in the case of RNA viruses, drives viral evolution in the
form of tolerable mutations to escape recognition by both cell-intrinsic and -extrinsic immune
responses (113, 188, 245). The dynamic “arms race” between host and pathogen has resulted in
convergent evolution observed in viruses from disparate families that target similar cellular
immune sensing pathways. Cells constitutively express both cytosolic and membrane-bound
proteins referred to collectively as pattern recognition receptors (PRRs), which bind conserved
pathogen signatures. Examples of membrane-bound sensors include the plasma membrane (PM)
localized Toll-like receptors (TLRs), TLR2 or 4, which have been traditionally described as
sensors of bacteria-derived products such as bacterial lipopolysaccharide (LPS), and C-type
lectin receptors (CLRs). Both these families of receptors can also sense viral-encoded structural
proteins that contain carbohydrate- and lipid-rich moieties (85, 103). Additionally, intracellular
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TLRs that localize to endosomal membranes, like TLR3, 7 and 9, sense viral nucleic acids (103).
Additional viral nucleic acid sensors localize to the cytoplasm including the retinoic acid-inducible
gene I (RIG-I)-like receptors (RLRs), which include RIG-I and melanoma differentiating factor 5
(MDA5), both of which specifically recognize viral RNAs (29). More recently, cyclic GMP-AMP
synthase (cGAS) was identified as the cytoplasmic sensor for viral DNA (221). PRR sensing of
pathogen-derived ligands activates downstream signaling networks that converge and synergize,
leading to nuclear translocation of various transcription factors that modulate expression of
proteins involved in immune responses (Figure 1-1). These include members of the nuclear factor
kappa-light chain-enhancer of activated B cells (NF-κB), interferon regulatory factor (IRF),
activator protein 1 (AP-1) and signal transducer and activator of transcription (STAT) families
(212, 266).
Overview of NF-κB signaling
NF-κB refers to a superfamily of conserved, rapidly responding transcription factors
involved in regulating various cell processes including development, cell growth, apoptosis and
responses to cellular stresses such as infection (80). In mammals, the family is comprised of 5
members: p65 (RelA), RelB, c-Rel, p105/p50 and p100/p52, which function as either homo- or
heterodimers with the other members (81). A highly conserved Rel homology domain regulates
function including dimerization, nuclear translocation, and binding to DNA (151). Generally, the
NF-κB family members recognize a consensus 10bp DNA sequence, 5′-GGGRNYYYCC-3′
(R=purine, Y=pyrimidine, N=any base), in the promoter or enhancer regions of target genes (40).
Though different family members bind to similar sequences, specific responses are directed by
cell intrinsic factors in combination with input stimuli. Specificity of the family for particular binding
sites allows researchers to assess activation using reporter systems (luciferase, GFP, etc.) as a
surrogate for NF-κB activation. Signaling is tightly regulated: sub optimal activation, in the case of
infection, may permit pathogen persistence; excessive activation has been associated with
numerous immunopathologies including cancer and autoimmune disorders as a result of chronic
inflammation (45, 222).
2

There are two known NF-κB activation pathways: classical and alternative. Classical NFκB is ubiquitous, and primarily regulates cellular immune responses, cell growth and death (80,
81). The alternative signaling pathway is more specific to lymphoid cells and is crucial for
development in cells of that lineage (48). When the cell is at rest, all NF-κB members are
sequestered in the cytoplasm and require a proteolytic event for activation and subsequent
nuclear translocation. In the alternative pathway one half of the NF-κB heterodimer exists as a
precursor protein, p100, which is bound to RelB (p100/RelB). p100 contains inhibitor domains
that keeps the dimer cytoplasmic. Nuclear translocation requires proteosomal processing of p100
to p52, generating the activated p52/RelB heterodimer (207, 253). Classical signaling is primarily
mediated by the activation of the NF-κB heterodimer p65/p50, which is kept inactive in the
cytoplasm by NF-κB inhibitor alpha (IκBα) (Figure 1-2). Upon receptor binding/sensing of a
ligand, a series of phosphorylation events mediate recruitment and activation of downstream
kinase complexes. Phosphorylation of the Skp, Cullin, F-box containing (SCF) E3 ubiquitin ligase
complex mediates proteosomal degradation of IκBα, freeing the sequestered NF-κB heterodimer
to translocate and accumulate in the nucleus where it binds κB sites on the chromosome allowing
regulation of gene expression (Figure 1-2, (81)).
NF-κB can be activated by various PRRs, as well as receptors that sense early-secreted
cytokines like tumor necrosis factor alpha (TNFα). Effector kinases that regulate NF-κB signaling
also feed into other signaling pathways including the mitogen-activated protein kinase (MAPK)
pathway to activate additional transcription factors like AP-1, which together with NF-κB regulate
transcription of various genes involved in cell homeostasis. NF-κB regulates genes involved in
immune responses, including those that encode cytokines, receptors for direct immune
recognition and antigen presentation, and factors important for cell transmigration (167). Negative
regulators of NF-κB signaling, like IκBα, are also regulated by NF-κB, allowing for negative
feedback to dampen prolonged activation (81, 167).
NF-κB plays a crucial role during infection, in part, by regulating expression of
proinflammatory cytokines (114), which are among the earliest danger signals secreted during
3

infection. Acute inflammatory signals are important for recruiting rapidly responding leukocytes
[e.g. neutrophils, professional antigen presenting cells (APCs) like macrophages and dendritic
cells (DCs), and natural killer (NK) cells] to the site of damage in order to clear the infectious
agent and help prime the adaptive immune system (19). Because acute inflammatory responses
are important early in infection, many viruses encode proteins to subvert activation (117), while
others have evolved ways to manipulate NF-κB expression to positively regulate replication.
Certain viruses can activate NF-κB via virally encoded proteins to enhance replication (167). NFκB is essential for retroviral replication. In fact, NF-κB was first discovered in studies of human
immunodeficiency virus 1 (HIV-1) replication (153) where it was identified as a transcription
factor. Additionally, proinflammatory responses have been suggested to enhance cell targets for
HIV-1 and other viruses, further promoting infection (142). Conversely, the HIV-1 accessory
protein viral protein U (Vpu) has been demonstrated to interfere with NF-κB activation by binding
and sequestering the SCF E3 ligase complex which stabilizes IκBα (28) suggesting HIV-1 needs
to modulate NF-κB activation to efficiently replicate. Just like the host, chronically infecting viruses
can modulate the proinflammatory state of a cell to ensure efficient prolonged replication and
subsequent transmission. Some viruses that cause acute infections, particularly those that
manifest as hemorrhagic fevers, stimulate uncontrolled cytokine production which causes the
host to go into shock (166). Elucidating novel NF-κB activating pathways that may directly affect
viral replication is paramount to not only further our understanding of host-pathogen dynamics,
but also to identify potential new targets for therapeutics.
Overview of IFN signaling
Interferons (IFNs),of which there are three major characterized types (I, II, and III), are a
second class of cytokine, and like proinflammatory cytokines are also expressed during early
immune responses. Type I IFNs, primarily α and β, robustly activate the host antiviral state in an
auto- and paracrine manner through the Janus kinase/signal transducer and activator of
transcription (JAK/STAT) signaling pathway, downstream of binding to the IFNα/β receptor
(IFNAR) (212). IFN signaling activates the innate immune response through upregulation of
4

genes that code for interferon-stimulated genes (ISGs), as well as negative and positive
regulators of the pathway (Figure 1-1). Through a number of these upregulated ISGs, IFNstimulated cells can more readily undergo apoptosis upon viral infection to halt replication (214).
Moreover, IFNs help prime cells of the adaptive immune system by enhancing T cell effector
function and enhancing B cell humoral responses (62, 115).
ISGs present a major hurdle to viral replication across many disparate families (196).
Viruses can dampen the antiviral response by targeting both direct expression of IFNs and IFNmediated signaling in infected cells (Figure 1-1). Type I IFN expression is regulated, in part, by
IRFs. IRF3, which is ubiquitously and constitutively expressed in all tissue allowing for rapid
expression of IFNβ during infection, can be targeted by various viruses (11, 178). HIV-1 and
ebolavirus (EBOV) are enveloped viruses, retro- and filoviruses respectively, with distinct
replication cycles, express proteins that meditate direct degradation of IRF3 or block IRF3
activation by preventing nucleic acid association with cytoplasmic PRRs, respectively (36, 208).
Additionally, viruses can target the JAK/STAT pathway directly to decrease expression of ISGs
(154). Moreover, viruses can target ISGs directly (187). Viral genomes are typically very compact,
encoding proteins with multiple functions. These different strategies exemplify how viruses use a
limited number of encoded gene products to counter host defenses and ensure replication. Innate
immunity is the first line of host defense and broad recognition redundancy allows for pathogen
sensing at all stages of replication from entry to egress.

General Overview of Enveloped Virus Egress
Egress is the final step of viral replication. For both DNA and RNA enveloped viruses, this
process involves assembly of genetically encoded structural proteins at host membranes [either
plasma membrane (PM) or at intracellular structures that are topologically similar, like the Golgi
apparatus or endoplasmic reticulum (ER)]. These viral proteins subsequently facilitate budding
and release from the host cell. Viruses express two potential driving forces of membrane
vesiculation (i.e. formation of vesicles): the viral “core” proteins (e.g. capsid, matrix and/or
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nucleocapsid) and the viral envelope glycoprotein(s). Viral “core” proteins assemble into higher
order oligomeric structures prior to or at the site of budding providing the scaffold on which
nascent virions are generated (Figure 1-3). “Core” proteins themselves are thought to be the
major drivers of membrane curvature. Mechanistically, this can occur through direct shallow
penetration into the inner leaflet of the PM, disrupting membrane order to induce curvature (159,
209); this parallels what is observed with numerous cellular molecules (e.g. BAR domain
containing proteins, the clathrin adaptor epsin, charged phospholipids) that can sense and/or
induce similar morphologic changes at membranes (133). Viral glycoproteins, which stud the
surface of the viral particle and mediate entry into host cells, are targeted to the site of budding
where some can potentiate membrane coalescence and mediate low levels of vesicle formation
(39, 139, 145, 161, 237), a property that is thought to enhance viral assembly at sites of budding
(132). The budding process is tightly orchestrated and requires, in many cases, the aid of cellular
proteins for completion (38).
Though viral structural proteins can initiate vesiculation at sites of budding, many
enveloped viruses encode, within structural proteins, short amino acid motifs known as latebudding domains (l-domains) that recruit host cell machinery to complete the budding process
(68). The endosomal sorting complexes required for transport (ESCRT) proteins are commonly
recruited by viral protein l-domains. Many viruses are dependent on this machinery to complete
release from the host cell. Under normal cellular conditions, the ESCRT proteins (ESCRT-0, -I, -II
and -III), perform a topologically similar function during biogenesis of multivesicular bodies
(MVBs), which involves formation and sorting of vesicles containing ubiquitinated cargo, a
process conserved from yeast to humans (12, 13, 102). Recruitment of ESCRT proteins is a
highly conserved mechanism shared by disparate families of enveloped viruses (23). For
example, HIV-1 and EBOV both recruit the ESCRT-I protein TSG101 via a P(T/S)AP motif found
on either HIV-1 or EBOV “core” protein, Gag (p6 region) and VP40 matrix, respectively (49, 64,
138, 233). Additionally, both viruses can also recruit other proteins to perform similar functions;
for instance, the ESCRT related proteins Alix/AIP1 and/or the HECT ubiquitin ligase NEDD4 via
6

additional l-domain motifs encoded within the “core” proteins (216, 248, 257). Engagement of
TSG101 leads to the recruitment of ESCRT-III complex members, like CHMP2 and CHMP4, in
the case of HIV-1 (149). Oligomerization of ESCRT-III complex proteins at the budding neck
constricts the membrane leading to scission (Figure 1-3A and B). The ATPase Vsp4 mediates
dissociation and recycling of ESCRT-III components for subsequent rounds of viral replication
recapitulating what is observed in cellular vesicle biogenesis (14). Other viruses, such as
influenza and respiratory syncytial virus (RSV), are capable of completing budding independent of
ESCRT machinery (31, 39, 230). The influenza M2 protein is recruited to sites of budding where it
inserts into the membrane and in tandem with the M1 protein drive membrane curvature and
release of viral particles (183).
Mutations in “core” protein l-domains or perturbation of the ESCRT pathway (genetically
via RNAi, dominant negative mutants, etc. or chemically via small molecule inhibitors, etc.) can
block viral budding (57, 76). Mutations typically affect the final scission step of budding.
Phenotypically, budding-defective viruses have incorporated cellular membranes, but particles
remain contiguous with the host cell (Figure 1-3C), leading to accumulation of immature virions
on the cell surface (68). These observations suggest viral budding is a targetable stage of
replication for therapeutic purposes and therefore an important stage of viral replication to study.
Expression of “core” proteins alone, like HIV-1 Gag or EBOV VP40, in cell culture systems is
sufficient to produce virus-like particles (VLPs), which are morphologically indistinguishable from
infectious virions. This has afforded researchers a tool to study the budding process in isolation,
using easier and safer VLP-based systems as surrogates of mature virion production for
numerous clinically relevant viruses that would otherwise require higher biosafety level
containment.
With or without host machinery, all enveloped viruses acquire a lipid shell derived from
host cell membrane upon budding. Many viruses are thought to bud at PM microdomains
commonly referred to as lipid rafts. Lipid rafts are small liquid-ordered domains suggested to
range between 10-200nm in size (175). These microdomains are heterogeneous in composition,
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primarily enriched in cholesterol, but also containing various sphingolipids and lipidated proteins
typically containing modifications like myristoylation or glycophosphatidylinositol (GPI) anchors.
Viral membrane lipid composition is thought to be important for steps in the viral replication cycle,
particularly at steps involving fusion like entry and egress (128, 238). HIV-1 and EBOV
membranes have been demonstrated to contain lipid raft-enriched molecules like the ganglioside
GM1 as well as the phospholipid, phosphatidylserine (20, 32, 160). Additionally, numerous
signaling platforms have been show to localize to lipid rafts (206). Moreover, there is a dense
actin cytoskeletal network underpinning lipid rafts: likely mediated by the interaction between raftlocalized signaling molecules with actin cytoskeleton regulatory components, which concentrate
upon receptor clustering within these specific microdomains (42). The actin cytoskeletal network
plays a role at various stages of viral replication including viral assembly and budding (226).
Enveloped viruses face the task of budding in an environment dense in cellular proteins. Many
viruses prevent bulk host protein incorporation into particles; however, certain host molecules
present at sites of budding can be preferentially acquired into nascent virions. Acquisition of host
molecules, in some instances, can be beneficial for viral replication as observed with enhanced
binding

and

entry

of

various

enveloped

viruses

that

become

enriched

with

host

phosphatidylserine (94, 147). As a result of incorporation into virions, host proteins like the
tetraspanins have been shown to impair infection by restricting membrane fusion. However, it is
believed HIV-1 can modulate tetraspanin expression on the cell surface during late stages of
infection to facilitate cell-cell transmission via virological synapses, while reducing production of
unfavorable syncytia (227). HIV-1 Vpu has been shown to downregulate a number of host
proteins to regulate HIV-1 egress and replication, including tetraspanins (74, 112), CD4 (250,
251) the NK coactivation receptor NTB-A (200) and Tetherin (158, 231).
The interplay between virus and raft-resident molecules at sites of concentrated signaling
platforms, suggests the cell could sense perturbation of this network during viral replication. ISGs
restrict various early events of viral replication, though there are a few examples of ISGs that can
block egress including ISG15, which interferes with ESCRT-viral “core” protein interactions, and
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viperin, which disrupts raft domains by perturbing lipid composition (155, 163, 164, 244). The
focus of this dissertation highlights previously understudied properties of lipid raft resident ISG
involved in blocking viral release, Tetherin, which we now know, not only restricts, but can sense
viral egress.

Tetherin: Discovery, Expression, Structure and Topology
Originally described as HM1.24, Tetherin was identified as a specific surface marker on
terminally differentiated B cells, suggesting a potential role in B cell development (67, 91). As an
antigen on immune cells, it was later assigned a cluster of differentiation (CD) nomenclature as
CD317 (267). The cDNA cloned from the associated gene product recognized by a monoclonal
antibody against HM1.24 matched a human gene, 540 base pairs in length (180 amino acids),
located on chromosome 19 annotated as bone marrow stromal cell antigen 2, BST2 (91),
consisting of 5 exons, 4 of which code for protein (162). The presence of STAT1/3, IRF1/2 and
IFN-stimulated gene factor 3 (ISGF3) binding sites upstream of the predicted translational start
site suggested expression could be immune modulated (162). Tetherin has been confirmed as a
bona fide ISG and is upregulated by IFNs, primarily type I, but also type II and type III (2, 157).
IFNβ- and γ-induced unphosphorylated STAT1 can stabilize Tetherin mRNA 48h after induction
allowing for potentially prolonged expression (41). Additionally, expression has also been shown
to be regulated by alternative mechanisms including a novel, uncharacterized IFN-independent,
IRF7-dependent pathway (22), the cytokine interleukin 27 (IL-27) (73) and regulated by a
chromosome proximal, IFN-stimulated long non-coding RNA (lncRNA) (101). Tetherin can be
highly upregulated in various IFN-responsive cultured cell lines though in primary cells and tissue
upregulation is thought to be more modest (54). Endogenously expressed Tetherin is present in
specialized cells across a variety of tissues, as well as cells of the immune system including
monocytes, macrophages, dendritic cells, NK cells, and B and T cells, (primarily those of Th1
lineage) (54, 129, 234), and preferentially expressed in certain transformed and invasive cell
types compared to non-transformed counterparts (33, 194, 239, 240, 242, 243, 252). To date,
Tetherin orthologues have only been identified in mammals, with the exception of an annotated
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protein that is Tetherin-like in sequence in Chinese alligator (accession #s: XP_006017475,
XP006017476), though it has not been tested for functionality. Additionally, in ruminants, gene
duplication of Tetherin allow for expression of functionally distinct isoforms (9, 152, 225).
Tetherin is a type II integral membrane glycoprotein of about 30-36kDa in size consisting
of a short N-terminal cytoplasmic tail, a transmembrane (TM) domain, long coiled-coil ectodomain
and a C-terminal GPI anchor (Figure 1-4A). It exists as a dimer under physiological conditions
(91, 109, 162). Dimerization is mediated by disulfide bond formation via three conserved cysteine
residues localized in the ectodomain. Monomeric forms of Tetherin dimerize in a parallel
orientation (160). Structurally, Tetherin is unusual, anchored at both the N- and C- termini, by a
transmembrane domain and GPI anchor respectively (53, 109). To date, the only other
mammalian protein identified with a similar structure is an alternative form of the prion protein
(215). Though it is universally accepted that Tetherin is GPI-anchored, at least one line of
evidence suggests that human Tetherin may express a second transmembrane domain in lieu of
the processed GPI-anchor signal sequence (5), presumably still allowing to be anchored at both
termini. The ectodomain, which is extracellular (or lumenal), is primarily a long coiled-coil (~165170 Angstroms (Å) relaxed) that can form higher ordered oligomeric species (83, 197, 223, 256).
Key hydrophobic residues in the ectodomain important for multimerization have been mapped via
structural data. Tetherin is proposed to also exist as a multimer of anti-parallel dimer of dimers
(~275Å) interacting via residues near the N-terminus (83, 197, 256). The ectodomain structure
has been described as “irregular”, with a N-terminal proximal kink observed via small angle x-ray
scattering approximately about a third of the way into the ectodomain. This feature is believed to
provide flexibility to the protein (197, 223). Though the cytoplasmic tail and GPI anchor are
primarily thought to mediate surface Tetherin partitioning, the ectodomain has also been
suggested to have some contribution to PM distribution (75). The Tetherin ectodomain has two Nlinked glycosylation sites that add ~14-17kDa of complex carbohydrate mass as observed by
diffuse immunoblot expression profiles. Tight protein resolution can be achieved using PNGase to
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remove N-linked glycans (Full-length, deglycosylated Tetherin is predicted to be ~19kDa in size;
confirmed by Western blot analysis after PNGase treatment) (6, 109).
Tetherin has a short N-terminal cytoplasmic tail, 21 amino acids in length (Figure 1-4A).
Residues in the tail are important for trafficking and localization. Tetherin localizes primarily to
detergent-resistant microdomains at the PM, though it is also present in intracellular
compartments like the trans-Golgi network (TGN) and endosomes (109). Trafficking between
these compartments is mediated by a tyrosine-based sequence in the cytoplasmic tail that
resembles overlapping putative recycling motifs (Figure 1-4A). In both rat and human Tetherin,
the dual-tyrosine motif engages the clathrin-associated adaptor proteins (AP) complexes 1 and 2.
The AP2 complex mediates Tetherin endocytosis from the PM to endosomes where AP1
engages and redirects cargo to the TGN where presumably Tetherin is transported back to the
PM (140). Mutations at both tail tyrosines (Y6, Y8) in the motif are required to fully disrupt
Tetherin intracellular trafficking, leading to PM stabilization (140, 181). Individual tyrosine
mutations have no discernable localization defect, though each residue has been proposed to
interact differently with trafficking machinery by yeast two-hydrid screening (Y6 with AP2 and Y8
with AP1), suggesting the individual tyrosine residues are perhaps not performing redundant
trafficking functions (140).

Tetherin Antiviral Function
Identification of Tetherin as a cellular restriction factor
The accessory protein Vpu has been described as essential for HIV-1 replication in
certain refractory cell lines (156, 184). HIV-1 lacking Vpu (delU HIV-1) was shown to accumulate
at the PM and within intracellular compartments (104). These observations suggested the
presence of a cell intrinsic factor involved in blocking HIV-1 replication that could be countered by
Vpu. Additionally, type I IFN stimulation enhanced the budding restriction phenotype (157), further
evidence that implicated the presence of an uncharacterized immune molecule. The factor in
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question would remain unknown for almost two decades from the time of the initial observations.
Neil et al., employing targeted screening of candidate proteins that differed in expression between
refractory and permissive cell lines, identified an IFN-inducible physiological “tether” that
prevented release of cell-free delU HIV-1. The gene associated with this phenotype was BST2,
previously described as HM1.24 and CD317, and thereafter referred to as Tetherin (158) due to
its “tethering” function of viral particles at the cell surface.
Breadth of Tetherin restriction and viral antagonists
In cell culture, Tetherin has been demonstrated to indiscriminately restrict a broad, and
continually expanding, list of enveloped viral families including alpha- (98, 165), arena- (177,
185), filo- (99, 100, 157), flavi- (168), rhabdo- (246), alphaherpes- (27, 263), gammaherpes(136), hepadna- (131, 255), orthomyxo- (134), paramyxo- (16), and representative viruses from
all families of mammalian retroviruses (including endogenous retroviruses (ERVs)) tested to date
(65, 69, 99, 158). Mouse knockout and knockdown models have suggested Tetherin contributes
to murine retrovirus restriction in vivo (97, 124, 224). Significant restriction in the murine knockout
models is believed to require additional IFN stimulation of endogenous Tetherin expression (124).
Additionally, Tetherin has been demonstrated to enhance cell-mediated immune responses
during infection (122).
With few exceptions, most Tetherin-sensitive virus families described to date are believed
to primarily bud from the PM. There is evidence that Tetherin in macrophages can restrict HIV-1
in intracellular MVB-like compartments called “virus-containing compartments” (VCCs) (43).
Hepatitis C virus (HCV), which buds into intracellular membranes, has been suggested to be
Tetherin-sensitive (46, 169), though work in an inducible system suggests only high Tetherin
expression levels have any significant effect (258). Recently, Tetherin was shown to also restrict
hepatitis B virus (HBV), which like HCV buds into intracellular membranes. The HBV work
suggests interactions in MVBs as Tetherin mutants that have aberrant trafficking and potentially
accumulate in intracellular compartments have potent function against HBV, but not against a PM
budding virus like HIV-1 (131). Additionally, herpes simplex 1 and human coronavirus 229E
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(HCoV-229E), both of which also bud into intracellular membranes, have been shown to be
Tetherin-sensitive (27, 241).
Many Tetherin-sensitive viruses encode proteins that counteract tethering function.
Mechanistically, most virally encoded Tetherin antagonists act by downregulating Tetherin (i.e.
removing from the sites of budding). Downregulated Tetherin can either be actively degraded or
sequestered intracellularly. Both the Kaposi Sarcoma-associated Herpesvirus (KSHV) K5 protein
and HIV-1 Vpu target Tetherin for degradation. KSHV K5 is an E3 ubiquitin ligase that mediates
Tetherin polyubiquitination, targeting it to the endolysosomal pathway for degradation (18, 136).
HIV-1 Vpu recruits the SCF-βTrCP E3 ubiquitin ligase complex via a cytoplasmic di-serine motif
to mediate ESCRT-dependent endolysosomal degradation of Tetherin (51, 92, 93, 148, 231). Vpu
binds Tetherin in the TGN to also prevent trafficking back to the PM (7, 52, 79, 195). Intracellular
sequestration is believed to contribute to maintaining low PM expression. The importance of Vpu
has been highlighted in humanized mouse models of HIV-1 infection, where Vpu was shown to
be important in early dissemination of the virus (47, 190). Both HIV-1 Vpu and KSHV K5 are
thought to interact with Tetherin intracellularly and target lysine residues in the Tetherin
cytoplasmic tail to mediate downregulation. A serine-threonine-serine region in the tail was shown
to be required for efficient Vpu targeting of Tetherin (44, 229), though the mechanism is unclear
(72).
Unlike HIV-1, most simian immunodeficiency viruses (SIVs) utilize the accessory protein
negative regulatory factor (Nef) to counter Tetherin. SIV Nef specifically engages simian Tetherin
through residues in the cytoplasmic tail (see below) and enhances recruitment of the AP-2
complex, which downregulates surface Tetherin. Contrasting Vpu or K5, Nef activity does not
result in loss of cellular Tetherin (264) suggesting a sequestration model. Though most SIVs
utilize Nef to counter Tetherin function, at least one SIV from the tantalus monkey (SIVtan) uses its
envelope glycoprotein (Env) (70). Inhibition by a retroviral Envs has also been observed in feline
immunodeficiency virus (FIV), various ERVs and HIV-2 (70, 118, 121, 150). A sequestration
model has been suggested for primate lentiviral Env-mediated antagonism of Tetherin and at
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least in HIV-2, occurs by enhancing Tetherin endocytosis via AP-2 (79). HIV-2 Env is thought to
mediate this interaction via its ectodomain, recognizing an N-terminal region of the Tetherin
ectodomain (55). Recently, the Chikungunya (CHIKV) accessory protein non-structural protein 1
(nsP1) (98) and herpes simplex virus 1 (HSV1) M (27) protein have been shown to downregulate
Tetherin though the mechanisms remain unclear
Other Tetherin antagonists have been described that utilize less conventional
mechanisms to counter Tetherin function. Filoviruses also utilize their glycoprotein, GP (100).
However, unlike SIV and HIV-2 Envs, filovirus GPs are thought to counter Tetherin without
actively removing it from sites of budding or degrading the protein (100, 126). Recent evidence
suggests that EBOV GP may facilitate incorporation of Tetherin in budding particles to overcome
restriction (71). FIV also does not actively downregulate Tetherin and is thought to require
incorporation into budding particles to function. However, unlike filoviral GPs, which can rescue
budding of and incorporate into different viral particles in the presence of Tetherin, FIV Env has
been shown to only rescue release of its cognate FIV “core” protein, p24, suggesting specificity
between FIV Env and FIV Gag (150).
Structures/domains important for viral particle tethering
Tetherin-restricted particles are distinct from viral particles still associated with host
membrane due to either mutations in l-domains or mutations in key ESCRT proteins. Particles
restricted by Tetherin have completed membrane scission and are considered mature (compare
Figure 1-3 and 4C). This tethering mechanism is direct and proteinaceous in nature as trapped
particles can be released from the PM by proteinase treatment (158). Tetherin requires anchoring
at both the N- and C-terminus to function. Rendering Tetherin a single membrane anchor protein
by either deleting the GPI anchor or TM domain allows surface expression, but prevents particle
retention (158, 171). These non-functional, single-anchored Tetherin mutants have been
observed to incorporate into budded virions (171). Restoring anchoring at either terminus by
engineering chimeric Tetherins partially restores tethering function. An artificial Tetherin (artTetherin) comprised entirely of domains (TM, coiled-coil ectodomain and GPI-anchor) from
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heterologous proteins has been demonstrated to be sufficient to tether HIV-1 particles,
suggesting that the cellular restriction function of Tetherin is inherent and primarily mediated by
structure (171). However, the potency of this art-Tetherin is greatly reduced compared to wt
Tetherin suggesting some degree of functional specificity to the native structure of the protein.
While art-Tetherin was expressed at the cell surface, the contributions of the individual
heterologous domains toward PM localization was not assessed.
Tetherin incorporation into particles favors GPI-insertion, while the N-terminal
transmembrane domain anchors the protein to the host cell (232). The cytoplasmic tail of Tetherin
has been shown to be excluded from raft domains (24), which presents a model where Tetherin
remains anchored outside the site of budding upon viral particle “tethering” at lipid rafts (Figure 14B and C). Tethered particles are internalized in a Rab5 dependent manner and trafficked to
endolysosomal compartments where they are degraded. Trafficking to endosomal compartments
exposes viral protein and nucleic acid to endosomal sensors that may further enhance immune
responses to infection. Multiple Tetherin dimers are thought to remain present at the assembly
site. Super-resolution microcopy suggests between 4-7 dimers of Tetherin within single
microdomains associate with a budding HIV-1 particle, though at least one report using
quantitative immunoblotting methods suggests this may be an underestimate based on certain
limitations of the microscopy technique (120, 232).
The length and post-translational modifications of the ectodomain of Tetherin appear to
be important for its function. The ectodomain is able to tolerate many triple alanine substitutions,
though there are specific regions and point mutations that disrupt function, correlating with
disruption of ectodomain structure (4, 75, 171). Tetherin glycosylation has been shown to be
dispensable for restriction of certain viruses like Lassa, Marburg and HBV, but not HIV-1 (131,
171, 185), though surface localization of the double-glycosylation mutant is greatly impaired
(171). Additionally, Tetherin dimerization appears to be important for tethering HIV-1, but not
Lassa virus (186). The cytoplasmic tail of Tetherin has been shown to be unnecessary for
tethering VLPs for various viruses. However, the tail is important in the context of viruses that
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encode antagonists that bind and/o target the tail with modifications that counter Tetherinmediated particle restriction.
Tetherin-retrovirus co-evolution
Intrinsic immune factors, including but not limited to TRIM5α, APOBEC3G and SAMHD1,
have all been demonstrated to potently restrict retroviral replication, limiting cell- and speciesspecific tropism (205, 218). This relationship has been well studied in primate lentiviruses, which
encode proteins that can antagonize the aforementioned cellular restriction factors (217). TRIM5α
is believed to block cross-species transmission of primate lentiviruses (77), while SAMHD1
appears to restrict cellular tropism of specific viruses like HIV-1 from infecting cells of myeloid
lineage, which express inhibitory levels of SAMHD1 endogenously (86, 111). APOBEC3G
presents a block to HIV-1 in target CD4 T cells, however, HIV-1 encodes the accessory protein,
viral infectivity factor (Vif), which targets APOBEC for degradation (137, 202). Tetherin has been
proposed to contribute to limiting primate lentiviral cross-species transmission (192). While
Tetherin indiscriminately restricts enveloped viruses, including representative members of all
retroviral families tested to date, primate lentiviruses specifically counteract Tetherin expressed in
cognate cell types. HIV-1 Vpu specifically antagonizes human Tetherin through unique
recognition via the TM domain (105, 143, 235). Sequence variations present in the TM domains
of various non-human primate Tetherins prevents recognition by HIV-1 Vpu. To date, only three
other SIVs [greater spot nose monkey (SIVgsn), mona monkey (SIVmon) and mustached monkey
(SIVmus)] have been identified that use Vpu to downregulate their cognate Tetherins through TM
recognition (192). Vpu also serves to downregulate surface CD4, a function that contributes to
efficient viral egress. Though all Vpus from SIVs and HIV-1 subgroup (with the exception of group
N) can efficiently downregulate CD4, only a subset these have been demonstrated to have antiTetherin function suggesting that the ability of certain Vpus to counteract Tetherin was an
acquired function through species-specific selective pressure (192).
HIV-1 arose from independent cross-species transmission events of either SIVcpz or SIVgor
(201). However, both of these viruses, like most other SIVs, use the accessory protein Nef.
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Tetherin recognition by Nef requires a five amino acid motif within the cytoplasmic domain found
on non-human primate Tetherins, but has been lost in human Tetherin. Consequently SIV Nef
does not counteract human Tetherin. Human Tetherin can be engineered to be Nef-sensitive by
the introduction of this motif (95, 265). Evidence of SIV adaptability to Tetherin has been
observed in SIV virus lacking the Nef protein (SIV delNef) passaged in vivo. Viral mutants with
compensatory changes in Env arise that confer anti-Tetherin function (198). This observed
adaption has demonstrated how lentiviral Env recognition of Tetherin could have evolved in
various SIVs that were thought to have given rise to the less prevalent HIV-2. SIVcpz is thought to
have arisen from transmission of SIVs from two different monkey lineages: one that utilized Vpu
and one that used Nef. Through selection, Nef ultimately become the dominant Tetherin
antagonist. This is also reflected in the potency of HIV-1 Vpus form the three different
phylogenetic groups (M, N, O). HIV-1 from group M have both strong anti-Tetherin and anti-CD4
function, in part, contributing to group M viruses becoming the pandemic strain. Based upon
these observations Tetherin has been implicated as a major barrier to primate lentivirus
speciation. Whether additional biological functions of Tetherin are also impacted by adaptation to
lentivirus infection is an open question and will be further discussed in Chapters 3 and 4.
Cellular functions of Tetherin
Tetherin is hypothesized to act as an organizer of lipid rafts, influencing diffusion and
distribution of proteins to and between microdomain clusters (25). This function is coupled to its
interaction with the actin cytoskeleton through its interaction with the protein RICH2 (25, 180).
Interfering with this interaction leads to disruption of apical actin network in polarized cells (180).
Regulation of monocyte adhesion to Tetherin-expressing endothelial cells has also been
observed (260). Additionally, the hamster Tetherin orthologue, Golgi-resident GPI-anchored
protein (GREG) is primarily Golgi-localized and involved in maintaining Golgi-apparatus integrity
(123). Of note, hamster Tetherin as well all other mammalian Tetherins contain long coiled-coil
domains that are reminiscent of golgin family proteins involved in regulating vesicular cargo
movement within the Golgi-apparatus. Though not topologically similar during function, golgin
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ectodomain homology potentially highlights the importance of Tetherin structure in its ability to
restrict viral particles (see Structure/Domains Important for Tetherin Viral Particles).
Recently, Tetherin was suggested to be involved in regulating autophagy and mitophagy by
sequestering a suppressor protein LRPPRC, preventing it from inhibiting Beclin 1 and Bcl-2
function (268).
Other immunological functions of Tetherin
Apart from being a cellular restriction factor, Tetherin has been shown to have additional
immune functions. Tetherin has been implicated in dampening type I IFN secretion in both murine
and human cells. Tetherin-expressing murine IFN-producing cells cross-linked by an immobilized
Tetherin mAb demonstrated reduced IFNα secretion after TLR stimulation with single-stranded
DNA (26). In human plasmacytoid dendritic cells (pDCs), Tetherin has been shown to interact
with the pDC receptor ILT7, leading to dampening of IRF3 dependent IFNα secretion in activated
pDCs (35). Recently, it was suggested that during particle restriction at the cell surface, Tetherin
epitopes that mediate interaction with ILT7 are occluded, which would allow pDCs to secrete IFN
(21). However, in the presence of Vpu, Tetherin molecules that were not downregulated were
observed to be relocated from budding sites, leading to pDC dysfunction (i.e. blocking IFN
secretion) (21) Additionally, Tetherin retention of budding particles on the cell surface enhances
natural killer (NK) cell mediated antibody-dependent cellular cytotoxicity (ADCC) (1, 8). Enhanced
presentation of HIV-1 specific epitopes on whole virions suggests Tetherin can serve as a link
between the innate and adaptive responses. Recently, Tetherin has also been suggested to
restrict long interspersed nucleotide element-1 (LINE-1) retrotransposition (66). Tetherin was
identified as a potent activator of the transcription factor NF-κB in a screen attempting to identify
novel and uncharacterized activators (191). NF-κB is important for many cell functions (see
below). The mechanism, including determinants, by which Tetherin activates NF-κB were
unknown prior to the start my thesis work. Additionally, it still remains unclear whether described
binding factors (e.g. ILT7) can affect NF-κB signaling. Additionally, the immune consequences of
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Tetherin-mediated activation of NF-κB, during or independent of, infection still remain to be
elucidated.

Tetherin as an Immune Sensor
Determinants of Tetherin-mediated activation of NF-κB
BST2 (aka Tetherin) was identified in a large cDNA screen for novel activators of the NFκB and MAPK pathways (141). Based upon this initial observation several groups, including ours
(see Chapters 2 and 3), have over the past 3 years identified determinants of, and requirements
for, Tetherin-mediated NF-κB activation (25, 44, 59, 60, 228). Tetherin appears to specifically
activate NF-κB, but not AP-1 or NF-AT (44, 59, 228). Tetherin-induced NF-κB signaling can be
dampened by a dominant-negative IKKβ suggesting signaling is activated via the classical
pathway (44, 59, 228). Tetherin isoforms [long (l-) and short (s-)] highlighted in Chapter 2 have
different signaling functions. s-Tetherin acts as a dominant-negative regulator of l-Tetherinmediated signaling (44). Additional signaling-null Tetherin mutants, including s-Tetherin, have
been shown to also act as a dominant negative, suggesting dimerization and/or multimerization of
the cytoplasmic tails may be important (see below). Tetherin-mediated signaling, like its viral
restriction function, is dependent on specific structural domains, as well as sequence motifs.
The cytoplasmic tail is critical and encodes several determinants of Tetherin-mediated
signaling. Loss of the dual-tyrosine motif significantly reduces signaling (44, 59, 228). Individual
tyrosine mutations have varying effects on signaling. Y6 within the dual-tyrosine motif has been
demonstrated as being crucial residue in what is believed to be a tyrosine-based signaling motif
similar to an ITAM (60). Tyrosine-based trafficking motifs (YxxΦ, where Φ=bulky hydrophobic)
resemble tyrosine-based signaling motifs observed in immunoreceptor tyrosine-based activation
motifs (ITAMs), which have individual tyrosine based motifs space by a series of non-specific
amino acids (YxxL/IX(6-8)YxxL/I). ITAMs are phosphorylated at the tyrosine residues, providing a
docking site for src-homology 2 (SH2) domain containing proteins, which typically are intracellular
kinases that amplify signaling pathways. Tetherin can be phosphorylated at either or both
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cytoplasmic tyrosine, Y6 or Y8 (60, 211). However, the Tetherin dual-tyrosine motif does not have
the proper spacing between tyrosine residues observed in classical ITAMs. hemITAMs, however,
represent a class of signal activating motifs with single tyrosine residues. This motif has been
observed on the dimeric immune sensor C-type lectin 2 (CLEC-2) and meditates recruitment of
Syk kinase. Tetherin dimerization is important for signaling suggesting that Tetherin
phosphorylation could parallel what is seen with receptors like CLEC-2 (87).
Triple alanine scanning mutagenesis has been performed on the cytoplasmic tail
identifying additional sets of amino acids that are required for signaling. Mutations at both an
arginine and valine residue believed to be under positive selection at positions 10 and 11 (RV)
abrogate signaling (59). Additionally, a region of basic residues that is proximal to the inner leaflet
of the PM was identified to be important. The arginine (R19) at the center of the set of triple
mutants in the basic patch has been identified as a rare polymorphism in humans (R19H).
Mutation at this site alone abrogates signaling (60, 191). Across all the point mutants tested,
ability to restrict particles was never compromised suggesting residues are specific for signaling
function.
Though the cytoplasmic tail plays an important role in signaling, additional residues and
domain have also been identified (Figure 1-5). Residues in the transmembrane domain have
been suggested (see below). The GPI anchor appears to be important, as addition of a premature
stop codon before the GPI-anchor signal sequence abrogates signaling (59). However, merely
deleting the C-terminal serine residues that could potentially act as GPI anchor sites still allows
Tetherin to signal (228). It remains unclear whether this deletion mutant has actually lost the
addition of the GPI-anchor. Replacing the GPI anchor with TMs from heterologous proteins,
including ones that localize to rafts, do not restore signaling to wt Tetherin levels though it is
suggestive that a second anchor is important (25). Furthermore, the chimeric proteins used in the
study did not restore wt Tetherin microdomain localization suggesting raft localization plays an
important role for signaling (25). Additionally, loss of both N-linked glycosylation dampens
signaling most likely due to mislocalization as this mutant has been previously observed to
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reduce PM expression (171). Based on the body of literature available, Tetherin-mediated
signaling is believed to be enhanced by clustering of Tetherin multimers at the PM. Mutations at
residues that promote multimerization (L70D, L123P) abrogate signaling (59, 228) and do not
promote enhanced activation during viral egress. Tetherin has been suggested to organize raft
microdomains (25). Changes in Tetherin structure, through viral particle sensing, presumably
enhances coalescing of raft microdomain and subsequent migration and recruitment of raft
resident signaling platforms.
Tetherin as a novel pattern recognition receptor
Tetherin restriction of a broad range of enveloped viruses coupled with this previously
uncharacterized signaling function suggested a role in sensing viral egress. In Tetherin
expressing cells NF-κB activation, as measured by reporter assay, was enhanced compared to
Tetherin-null or knockdown cells, using both VLP-based systems and replication competent
viruses (MLV and delU HIV-1) in stable cell lines. This correlated with enhanced cytokine mRNA
expression in primary CD4 T cells (59). Tetherin-mediated signaling leads to activation of various
cytokines including the proinflammatory cytokines IL-6 and CXCL10. When HIV-1 expresses Vpu,
reduced NF-κB activation is observed. Though a Vpu mutant (A14L) that has lost its ability to
interact with Tetherin allowed activation of NF-κB (59, 235), it is unclear whether this Vpu mutant
affects signaling independent of Tetherin as Vpu has been shown to dampen NF-κB by stabilizing
IκB (28). Additionally, enhanced IFNβ mRNA expression was observed in the presence of
replication competent virus. Tethered particles are thought to be endocytosed and degraded in
endolysosomal compartments. The current theory suggests that enhanced IFNβ is the result of
viral nucleic acid being sensed by an endosomal receptor. Sensing and subsequent signaling is
dependent on efficient assembly and budding of viral particles. L-domain mutant MLV fails to
robustly activate NF-κB. Replacing the mutant l-domain with the p6 region of HIV-1 restores
activation (59). Additionally, blocking endocytosis enhances signaling suggesting virion
accumulation plays an important role. Clustering of particles leads to aggregation of Tetherin at
the PM, a model that is also supported by the observation that Ab crosslinking of Tetherin at the
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PM also enhances signaling (59). Sensing of viral particles correlates with phosphorylation of the
dual tyrosine motif. Genetic and chemical perturbations suggest activation by the putative
hemITAM is Src and Syk kinase dependent. The interaction between Tetherin and the actin
cytoskeleton through RICH2 is crucial as knockdown of RICH2 or disruption of the actin
polymerization by cytochalasin D reduces the hypothesized Tetherin-mediated Syk activation
(60).
Tetherin-mediated signaling as an acquired function in humans during primate speciation
Regions in the cytoplasmic tail are thought to have undergone positive selection in
primates. Signaling by human Tetherin appears to be an acquired function from these
adaptations. This function, in part, has been suggested to have contributed to the selection of the
current HIV-1 pandemic strain, M; subtypes of which make up about 90% of the circulating cases
worldwide (82). Human Tetherin is the only primate Tetherin with signaling function identified to
date. Tetherins from chimpanzee, gorilla, African green monkey and rhesus macaques do not
signal, nor does Tetherin from mouse and various felids; a caveat of these findings being that
signaling was tested in human cells (59). It is unclear whether non-human Tetherin proteins
signal in the appropriate cognate cell, though NF-κB signaling is fairly well conserved among
mammals. Recently, two equine Tetherins were demonstrated to activate NF-κB in human cells
independent of a tyrosine-based motif (259). It is currently unclear whether they activate similarly
to what has been described for human Tetherin.
Tetherin antagonism by primate lentiviruses is specific. Important residues that have
evolved in primates contribute to hTetehrin signaling (Figure 1-5) including the five amino acid
Nef recognition motif, which impairs chimp Tetherin, the closest related Tetherin to humans.
Deletion of this Nef recognition sequence allows chimp Tetherin to signal; conversely,
introduction of this sequence into human Tetherin abrogates signaling (59). The RV region
described above is under positive selection in primates. The previously described RV tail
sequence and a two amino acid insertion into the TM only present in human and chimp Tetherin
are also important. Additionally, the STS region was previously identified to be important for Vpu
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mediated downregulation of human Tetherin (229). Introduction of the rhesus sequence (PIL), but
not the chimp sequence which is point mutation S5L, also abrogates signaling (60). This region is
explored in Chapter 3 of this dissertation.
Current model for Tetherin-mediated signaling
To summarize the current model from Galao et al of Tetherin-mediated activation of NFκB: Tetherin in a resting cell is believed to interact with RICH2 via its cytoplasmic domain. In this
model, the actin cytoskeleton, in part mediates sensing of viral particles. Tethered-particles
clustered at the cell surface enhance phosphorylation of the dual-tyrosine motif in the Tetherin
cytoplasmic tail by a currently unknown Src kinase. This phosphorylated tyrosine motif is believed
to act as a hemITAM, which recruits Syk kinase. Syk subsequently activates a series of effectors
including TRAF2/6 and the TAK1 complex leading to downstream liberation of NF-κB. NF-κB
induced genes are upregulated (Figure 1-4, (60)), though their role downstream of Tetherin, in
vivo, is unknown.

Project Aims
Tetherin restricts a wide range of clinically relevant enveloped viruses, including HIV-1. A
large body of work has elucidate how Tetherin directly “tethers” budding viral particles. Functional
studies have identified the structural features required for viral particle restriction. The Tetherin
cytoplasmic tail has been shown to be dispensable for tethering particles. However, we know
aspects of Tetherin biology, like trafficking, are regulated by motifs in the tail. Additionally, virally
encoded Tetherin antagonists can bind/target sequences in the tail to mediate PM
downregulation. The human Tetherin cytoplasmic tail has few conserved features across other
orthologues apart from the previously described dual-tyrosine motif. We sought to identify
additional features of the cytoplasmic tail that could potentially regulate poorly characterized
aspects of Tetherin biology.
In Chapter 2, we describe an internal methionine in the cytoplasmic tail of human
Tetherin, which is highly conserved in Tetherin orthologues. We hypothesized this codon could
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act as a downstream in-frame translation initiation site (TIS) based on analysis the Kozak
sequences flanking the putative upstream start codon and the conserved downstream AUG.
Because this would yield a truncated isoform lacking, at minimum, the dual-tyrosine motif, we
hypothesized that the full-length and truncated isoforms could be functionally distinct. There was
precedent for this hypothesis. Blasius et al. identified Tetherin cDNA from murine cells, which
only encoded a downstream methionine compared to the full-length annotated sequence (26).
Upon cloning the full-length form, Blasius et al. observed reduced expression off the upstream
start codon leading to the hypothesis that the second AUG codon could be the primary start site
and that the full-length form could have “instability or altered cellular localization” (26).
Functionally we assessed the ability of the Tetherin isoforms to restrict particle release in the
presence and absence of the Tetherin antagonist Vpu, and to activate NF-κB. Because NF-κB
plays an important role in priming early responses to viral infection and Tetherin acts to restrict
virus, we sought to elucidate this understudied Tetherin function in an attempt to develop a more
comprehensive picture of Tetherin as an innate immune factor.
Observations described in Chapter 2, in combination with concurrent work out of the Neil
and Guatelli groups implicated the dual-tyrosine trafficking motif for Tetherin-mediated signaling.
We initially hypothesized that differences in signaling between l- and s-Tetherin isoforms would
help focus on the most important determinants for signaling. It has since been suggested that the
tyrosine motif can act as a hemITAM (60). However, numerous determinants have been identified
beyond the dual tyrosine motif within and outside of the cytoplasmic tail (59, 60, 191, 228), which
suggests a more complex signaling model. Syk has been suggested to interact with Tetherin via
the hemITAM, however a direct interaction has not been definitively shown. The studies
described in Chapter 3 were started before a hemITAM was implicated in the current model of
Tetherin signaling. During the process of identifying determinants of signaling, we discovered that
our data, from a series of single and multiple point mutations, does not appear to align with the
current model described above, thereby questioning the mechanism by which Tetherin is
activating NF-κB. In Chapter 3 we assess the importance of the tyrosine residues within the
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hypothesized hemITAM, as well as suggest the role of an amino terminal motif that we
hypothesize regulates Tetherin-mediated signaling.
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Figure 1-2. Schematic of classical NF-κB signaling through a surface receptor. When the
cell is rest, NF-κB dimers remains cytoplasmic, sequestered by IκB. Ligand binding by a receptor
leads to receptor or adaptor phosphorylation at signaling motifs like ITAMs, which recruits SH2
containing kinases, like Src- or Syk-family kinases. Central to activation of NF-κB via stimuli, like
TNFα and bacterial LPS. is the TAK1 complex. Phosphorylation leads to activation the IκB kinase
(IKK) complex, which is comprised of 3 subunits, IKKα, IKKβ and NEMO. The IKK complex
mediates ubiquitination of IκB and subsequent proteosomal degradation, which frees NF-κB for
nuclear translocation. NF-κB regulates expression of various genes involved in immunity,
including proinflammatory cytokines.
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Figure 1-3. Schematic representation of viral egress. (A) Oligomerized or monomeric viral
structural protein subunits are targeted to sites of budding. Aggregation of viral proteins at the
membrane induces curvature, initiating the budding process. Viral “core” proteins recruit ESCRT
proteins like TST101 (green circle) to facilitate budding and scission. TSG101 recruitment leads
to ESCRTIII complex (green ring) constricting budding neck, leading to scission (B) Fully budded
enveloped virion completed scission, acquiring host membrane and specific host molecules in the
process. (C) l-domain mutant viruses and/or mutations in ESCRT proteins prevents viral budding.
Particles remain “tethered” to plasma membrane via contiguous host membrane.
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Figure 1-4. Cartoon representations of Tetherin domains, topology and function. (A) Linear
cartoons highlighting important functional domains. Top: Graphical depiction of domains and
modifications with * denoting cysteine residues involved in disulfide bond formation. Two sites of
N-linked glycosylation are labeled. Bottom: Linear domain model. Residues of the cytoplasmic tail
of human Tetherin labeled. Dual-tyrosine motif underlined and aligned with putative consensus
for
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TM=transmembrane domain (B) Tetherin topology. Top left: Topological cartoon representation of
a parallel Tetherin dimers (black monomer in front, grey monomer in back) anchored at the
plasma membrane. Raft domain represented by yellow shapes. Top right: Cartoon depiction of
Tether tetramers interacting via N-terminal hydrophobic faces on ectodomain Bottom: Looking
down on cell surface, Tetherin molecules depicted spanning lipid rafts (yellow clusters) as dimers
and tetramers (C) Tetherin localization at sites of budding allows incorporation of one anchored
end into particle (preferably the GPI anchor), while other end remains membrane associated with
host membrane. Tethered particles are subsequently endocytosed and degraded.
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Figure 1-5. Determinants of Tetherin-mediated signaling. Cartoon model of linear Tetherin
structure described in Figure 1-4A. Red highlighted sequences on cartoon structure abrogate
signaling when mutated in human Tetherin *= triple cysteines substitution. Alignment of
cytoplasmic tail and partial sequence of tail proximal TM sequence expanded. Cytoplasmic tail
residues highlighted in red are single point mutations identified in Chapter 4 that drastically
impact signaling. Residues highlighted in blue previously identified as important for signaling in
combination via triple alanine scanning mutagenesis. Residues in gold when introduced into the
human Tetherin background, abrogates signaling. Tetherins observed to signal highlighted in
green.
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Figure 1-6. A proposed model for Tetherin-mediated NF-κB signaling. When cell is at rest,
Tetherin associates with actin cytoskeleton via RICH2. Activation through Tetherin clustering by
sensing assembling/budding viral particle (or Ab crosslinking) leads to actin-dependent
phosphorylation of cytoplasmic tyrosine motif by an unknown src-kinase. Syk recruitment to this
hemITAM activates downstream complexes consisting of TRAF2/6, TAK1, and TAB1/2, which
leads to IKK complex activation. IKK mediates ubiquitination of IκB, liberating NF-κB for nuclear
translocation where it upregulates genes like IL-6 and CXCL10. Unlike other traditional TAK1
mediated signaling pathways, Tetherin does not activate AP-1.
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ABSTRACT

Tetherin (BST-2/CD317/HM1.24) is an IFN induced transmembrane protein that restricts
release of a broad range of enveloped viruses. Important features required for Tetherin activity
and regulation reside within the cytoplasmic domain. Here we demonstrate that two isoforms,
derived by alternative translation initiation from highly conserved methionine residues in the
cytoplasmic domain, are produced in both cultured human cell lines and primary cells. These two
isoforms have distinct biological properties. The short isoform (s-Tetherin), which lacks 12
residues present in the long isoform (l-Tetherin), is significantly more resistant to HIV-1 Vpumediated downregulation and consequently more effectively restricts HIV-1 viral budding in the
presence of Vpu. s-Tetherin Vpu resistance can be accounted for by the loss of serine-threonine
and tyrosine motifs present in the long isoform. By contrast, the l-Tetherin isoform was found to
be an activator of nuclear factor-kappa B (NF-κB) signaling whereas s-Tetherin does not activate
NF-κB. Activation of NF-κB requires a tyrosine-based motif found within the cytoplasmic tail of the
longer species and may entail formation of l-Tetherin homodimers since coexpression of sTetherin impairs the ability of the longer isoform to activate NF-κB. These results demonstrate a
novel mechanism for control of Tetherin antiviral and signaling function and provide insight into
Tetherin function both in the presence and absence of infection.
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AUTHOR SUMMARY

Regulation of innate immunity is critical to maintain a balance between control of a
perceived threat and immunopathology. The interferon induced cellular factor Tetherin has been
shown to restrict budding of a broad range of enveloped viruses including the human
immunodeficiency virus. Though Tetherin appears to be a bona fide viral restriction factor,
additional cellular functions have been observed including an involvement in actin cytoskeleton
organization in polarized cells, regulating interferon secretion and signaling through nuclear
factor-kappa B (NF-κB). Our studies present a mechanism by which Tetherin function is regulated
at the translational level through the production of alternatively translated isoforms. The short
isoform of Tetherin was observed to be significantly more resistant to HIV-1 Vpu. In contrast, the
longer isoform can induce NF-κB activity, a function lacking in the short isoform. Critical NF-κB
signaling residues include a dual tyrosine motif, which is only present in the long isoform.
Identification of these isoforms helps to illuminate how Tetherin functions, not only as a restriction
factor, but also as a signaling molecule. These data highlight a previously unappreciated level of
regulation and furthers our understanding of additional Tetherin functions.
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INTRODUCTION

Tetherin (BST-2/CD317/HM1.24) is an interferon (IFN) induced, type II transmembrane
glycoprotein which has been shown to function as an intrinsic antiviral factor that restricts release
of a broad range of enveloped viruses, including members of the arenavirus (177, 185), filovirus
(100, 185), gammaherpesvirus (136, 170), paramyxovirus (177), retrovirus (9, 69, 99) and
rhabdovirus (189, 246) families. Selective pressure from Tetherin on the aforementioned families
of viruses is evident because many of these Tetherin sensitive viruses encode proteins that
counter Tetherin function. To date, several virally encoded Tetherin antagonists have been
identified, a few of which function through different mechanisms. These include HIV-1 Vpu (158,
231), KSHV K5 (136), SIV Nef (95), HIV-2 and SIV Env (70, 118), and ebolavirus GP (100).
Tetherin has an unusual topology that has been shown to be critical for function as a
restriction factor. Tetherin is a lipid raft resident protein anchored to the cellular membrane by a
N-terminal transmembrane domain and a C-terminal GPI anchor (109). Localization to sites of
enveloped virus budding and anchoring at both ends is needed for Tetherin function as a cellular
restriction factor through a direct “tethering” mechanism which bridges the viral and host
membranes (171). The N-terminus also includes a cytoplasmic tail, which contains a tyrosinebased motif that mediates trafficking between lipid rafts at the plasma membrane and intracellular
compartments, including the trans-Golgi Network (TGN), via adaptor complexes involved in
clathrin-mediated endocytosis (140, 181). Additionally, the Tetherin cytoplasmic tail has a serinethreonine-serine stretch and lysine residues that were identified as targets for HIV-1 Vpumediated tetherin downregulation through the recruitment of cellular ubiquitin ligase complexes
(51, 148, 229).
A number of studies have examined the ability of Tetherin to function as a cellular
restriction factor; however, there is evidence that Tetherin has additional roles that may be
important both in the presence and absence of viral infection. Tetherin was originally described as
a marker on differentiated B cells and was suggested to be involved in B cell development (67,
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91). It is apparent now that Tetherin is constitutively expressed on various other cells of the
immune system including macrophages, plasmacytoid dendritic cells (pDCs) and T lymphocytes
(26, 234). Tetherin is also preferentially expressed on the surface of various transformed and
metastatic cell types (33, 162), though whether Tetherin is actively contributing to the transformed
state of the cell is unknown. Additionally, Tetherin has been proposed to act as a scaffold protein
in polarized cells (180) and contribute to monocyte adhesion to endothelial cells (260). Apart from
directly restricting viral egress, Tetherin has been shown to have immunomodulatory properties.
Tetherin regulates cytokine secretion in murine (26) and human pDCs. In human pDCs, Tetherin
acts as a ligand for immunoglobulin-like transcript 7, which results in modulation of Toll-like
receptor-mediated IFN and proinflammatory cytokine secretion (35). Additionally, a cDNA screen
identified BST-2 (aka Tetherin) as one of several uncharacterized cellular factors that could
activate NF-κB (191). However, this potential role for Tetherin in signaling has not been further
explored.
Here we identify a previously undescribed short isoform of human Tetherin generated by
alternative translation initiation at an in-frame codon 33 nucleotides downstream of the canonical
translation start site which results in the production of two Tetherin species. The long (l-) and
short (s-) Tetherin isoforms are generated in both cultured and primary human cells. Importantly,
the two isoforms have distinct biological properties. s-Tetherin, which lacks 12 residues present
in the long isoform, is significantly more resistant to HIV-1 Vpu-mediated downregulation and
consequently more effectively restricts HIV-1 release in the presence of Vpu than l-Tetherin. In
contrast, the ebolavirus glycoprotein (GP) effectively counters both Tetherin isoforms. We also
find that Tetherin is a significant activator of NF-κB.

However, the Tetherin isoforms have

dramatically different signaling potential, with NF-κB activation requiring a tyrosine motif found in
the l-Tetherin isoform but absent in s-Tetherin. These observations provide insight into how the
expression of alternatively translated Tetherin isoforms regulates multiple cellular functions and
begins to shed more light on a poorly characterized signaling property.
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RESULTS

Alternative translation initiation produces two isoforms of Tetherin
Sequence analysis of the cytoplasmic tail of Tetherin revealed minimal amino acid
conservation across species. Residues that were highly conserved included two cytoplasmic
methionine residues and a dual tyrosine motif (Figure 2-1A), previously found to be involved in
Tetherin trafficking between the plasma membrane and intracellular compartments (140, 181).
Methionine codons can function as translation start sites when they are flanked by a Kozak
consensus sequence, which influences ribosomal binding at the site of translation initiation in
eukaryotic cells.

Analysis of the human tetherin mRNA sequence revealed that the Kozak

sequences flanking the first AUG (M1) appears to be a potentially “leaky” signal due to a nonconsensus pyrimidine at the -3 position (Figure 2-1B) (107). The downstream methionine (M13)
appears to be a stronger translation start site with compensatory cytosine residues at positions -1
and -2, which could enhance the strength in the absence of the purine in the -3 position (106).
Although neither of these methionine residues can be defined as strong Kozak consensus start
sites, both sequences display conservation at the important +1 through +4 positions. Analysis of
the mRNA sequences of Tetherin from other species revealed a similar potentially “leaky” Kozak
signal for the upstream methionine (Figure 2-S1), suggesting that production of multiple isoforms
may be a conserved Tetherin characteristic.
To address whether alternatively initiated Tetherin isoforms could be produced, mutations
that individually abrogated each of the AUG codons were generated in the wt cDNA (Figure 22A). N-linked glycosylation of Tetherin produces a heterogeneous population of proteins that is
not well resolved by electrophoresis [(6) and Figure 2-S2], complicating unambiguous
identification of the observed Tetherin bands.

Therefore, to better differentiate the potential

isoforms that are predicted to differ by 12 residues (~1.5 kDa), lysates from transiently expressing
cells were treated with Peptide: N-Glycosidase F (PNGase) to remove N-linked glycosylation
before analysis by Western blot.

Analysis of deglycosylated lysates from HT1080 cells
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expressing the wt Tetherin cDNA reveals two major bands of between 15-20kDa (Figs. 2-S2 and
2-2B); the predicted sizes of proteins initiated at the M1 and M13 translation initiation sites is
approximately 18 and 16.5kDa respectively. Transient expression of the wt tetherin cDNA
produces more of the larger form compared to the smaller species. Expression of the M13I
mutant in HT1080 cells produces a single major product that aligns with the larger protein species
seen in wt cDNA transfected cells (Figure 2-2B). The M1A mutant, that abolishes the upstream
potential initiation site, generates a protein that migrates similarly to the smaller species produced
by wt cDNA. Co-transfection of plasmids expressing the M1 and M13 mutants recapitulates the
pattern seen with wt Tetherin (Figure 2-2B). Overall, these data demonstrate that transient
expression of the wt cDNA produces two alternatively initiated species that we refer to as the lTetherin (long) and s-Tetherin (short) isoforms.
To address whether expression of the s-Tetherin isoform was due to translational
leakage, an optimized translational initiation sequence was generated by converting the
sequence at the -3 position of the upstream M1 ATG in the wt Tetherin cDNA from a pyrimidine
(T) to a purine (A). Upon introduction into HT1080 cells of a vector with a strong Kozak sequence
at the M1 AUG, expression of l-Tetherin was greatly enhanced while expression of s-Tetherin
was almost undetectable (Figure 2-2B).

This mutational analysis, coupled with the data

presented above, demonstrates that Tetherin utilizes a non-canonical Kozak sequence to
produce alternatively initiated proteins with different cytoplasmic tails.
To determine whether both isoforms of Tetherin are endogenously expressed, nonstimulated and interferon (IFN)-stimulated 293T, HT1080, HeLa, primary human CD4 T-cell
lysates were analyzed as described above and compared to 293T cells transiently expressing the
M13I and M1A mutants. As predicted from previous results, no Tetherin was seen upon analysis
of deglycosylated proteins from unstimulated 293T and HT1080 cells. Interferon treatment of
293T and HT1080 cells induces Tetherin expression and upon PNGase treatment, collapses a
diffuse banding pattern to two bands that migrate similarly to the two isoforms produced by
st

transfection of l-Tetherin and s-Tetherin encoding plasmids (Figure 2-2C, 1 panel and Figure 238

S3). This demonstrates that IFN stimulation produces both alternatively initiated forms of
Tetherin. Analysis of lysates from HeLa cells, which constitutively express relatively high levels of
Tetherin, revealed the presence of the doublet in the absence of IFN (Figure 2-2C, 2

nd

panel).

Both bands appear to be enhanced after IFN stimulation (Figure 2-S3). Similarly to HeLa cells,
analysis of untreated primary CD4 T-cells revealed two Tetherin species that were enhanced
rd

upon IFN stimulation (Figure 2-2C, 3 panel). In all cell types tested for endogenous expression
of Tetherin, roughly equal expression of both isoforms was observed after 48 h of IFN stimulation.
Expression of the M13I and M1A mutants in 293T cells produced the l- and s-isoforms seen
above in HT1080 cells, however in this case smaller molecular mass species are seen (denoted
th

by an asterisk on the 4 panel of Figure 2-2C and throughout the manuscript). These species are
only observed in transiently expressing 293T, and not in transfected HT1080 or interferoninduced cells. Though the derivation of these species is unclear, they may represent a precursor
or proteolyzed product. Finally, analysis of cells transiently expressing rhesus or murine Tetherin
cDNA or IFN treated murine J774 cells demonstrated a doublet indicative of production of two
isoforms (Figure 2-S4A and B) indicating that production of long and short isoforms of Tetherin is
a highly conserved feature. In contrast, the rhesus cell line FRhK-4 appears to produce only a
single Tetherin isoform (Figure 2-S4B). Taken as a whole, the presence of these isoforms in
numerous cell types, under various conditions and in multiple species is suggestive of important
biological roles for the newly identified l-and s-Tetherin isoforms.

Tetherin isoforms assemble into homo- and heterodimers
Tetherin exists as a disulfide-linked dimer that is believed to represent the functional form
necessary for viral restriction. Structural studies on the ectodomain suggest that Tetherin dimers
may also form higher order aggregates, which may be functionally important (83, 197).

To

address whether the isoforms interact to form heterodimers, lysates from HT1080 cells
expressing wt, l- or s-Tetherin were separated under non-reducing conditions and analyzed by
Western blot. Expression of either the l- or s-Tetherin isoform produced single bands of a
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molecular mass indicative of homodimer formation (Figure 2-S5A). In comparison, the wt cDNA
produced a broader expression profile that overlapped with the l- and s-profiles suggesting both
homo- and heterodimer formation (Figure 2-S5A). To directly assess the interaction of the l- and
s- isoforms, a C-terminally FLAG-tagged l-Tetherin and N-terminally AU1 tagged s-Tetherin were
co-expressed and immunoprecipitated using antibodies to the epitope tags (Text 2-S1).

As

anticipated for efficient heterodimer formation, immunoprecipitation with either tag effectively coprecipitated the other isoform (Figure 2-S5B). As discussed below, the ability to form homo- and
heterodimers may have significant effects upon the biological activities of Tetherin.

Both Tetherin isoforms restrict particle release, but differ in their sensitivities to viral
antagonists
The cytoplasmic tail of Tetherin is dispensable for function as a viral restriction factor
(171). However, residues in the cytoplasmic tail have been shown to confer sensitivity to viral
antagonists. For example, a serine-threonine-serine sequence, which is unique to l-Tetherin, has
been found to be important for efficient Vpu antagonism (229). Using a transient HIV-1 virus-like
particle (VLP) budding assay, the l- and s- isoforms were analyzed for their ability to restrict viral
release. Both isoforms were effective viral restriction factors and displayed strong inhibition of
HIV-1 VLP release (Figure 2-3A, top panel). The antiviral activity of wt Tetherin, which expresses
both Tetherin isoforms, is antagonized by co-expression of HIV-1 Vpu with VLP release
correlating with the level of Vpu expression. In contrast, antiviral activity of the l-Tetherin isoform
is exquisitely sensitive to Vpu with significant rescue of viral budding seen at the lowest levels of
Vpu expression analyzed (Figure 2-3A, top panel). Additionally, a decrease in l-Tetherin protein
levels was readily observed at higher levels of Vpu expression (Figure 2-3A, third panel).
Conversely, the s- isoform appears to be resistant to antagonism by Vpu, with very little VLP
budding rescue observed at the highest levels of Vpu tested (Figure 2-3A, top panel). Moreover,
turnover of the s- isoform also appears to be resistant to Vpu as there was no obvious decrease
in s-Tetherin expression even at the highest levels of Vpu (Figure 2-3A, third panel).
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To determine whether the differential sensitivity to viral antagonists was a common
property of the Tetherin isoforms, sensitivity to a different viral factor, the ebolavirus glycoprotein,
GP, was analyzed. GP is hypothesized to rescue virus budding in Tetherin-expressing cells
through a non-cytoplasmic tail-associated mechanism (127) and might therefore be predicted to
interact similarly with both Tetherin isoforms. In contrast to the results with Vpu, within the range
of GP levels tested, GP-mediated rescue of budding was similar for wt and the two Tetherin
isoforms (Figure 2-3B, top panel). Additionally, total cellular Tetherin protein levels appeared
unchanged for wt Tetherin and each individual isoform even at the highest levels of ebolavirus
GP co-expression (Figure 2-3B, third panel).
To determine whether the differential particle release by the isoforms in response to Vpu
was due to altered Tetherin cell surface levels, flow cytometric analysis of live cells stained for
Tetherin was performed. In Vpu expressing cells, surface wt Tetherin expression followed the
same trend as the total cell Tetherin protein levels (compare Figure 2-3A third panel and Figure
2-4). Surface expression of l-Tetherin was downregulated by Vpu to a greater extent than the sTetherin isoform, while wt Tetherin appeared to have an intermediate level of downregulation
(Figure 2-4). Analysis of lysates from the cells prepared in parallel with those used for flow
cytometry confirmed the enhanced degradation of l-Tetherin compared to s-Tetherin observed
above in both the reduced monomers and stable dimers. Additionally, preferential degradation of
the l-isoform was seen in lysates of cells expressing wt Tetherin and high levels of Vpu (Figure 24; arrow). In comparison, there is no difference in the effect of ebolavirus GP on surface or total
levels for the l- and s- isoforms though a decrease in surface staining was observed across all
Tetherin constructs tested. The minimal 2-fold decrease in the mean fluorescence intensity of
Tetherin surface staining observed in ebolavirus GP expressing cells is consistent with steric
shielding of epitopes previously documented for this glycoprotein (56, 179) and appears similar to
the slight decrease noted recently by Lopez and colleagues (127). Overall, these observations
suggest that the Tetherin isoforms can have different sensitivities to viral antagonists, which may
have important consequences during natural infection.
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Resistance to Vpu antagonism requires mutations in the tyrosine and serine/threonine
motifs in Tetherin
To further explore the basis for the relative Vpu resistance of s-Tetherin compared to lTetherin, a series of mutations were engineered into the 12 residue region unique to l-Tetherin
(Figure 2-5A). Two motifs within this region have been proposed to play a role in Vpu mediated
antagonism; a dual tyrosine motif (amino acids 6 and 8, Figure 2-5A) involved in endocytic cycling
of Tetherin (195) and a stretch of serine and threonine residues (amino acids 3 to 5, Figure 2-5A)
that can be ubiquitinated (72, 229). Analysis of HIV-1 VLP release from 293T cells transiently
expressing a tyrosine mutant AxA produced in l-tetherin expressing cDNA shows decreased
release in response to Vpu as compared to parental l-Tetherin (lane l-AxA, Figure 2-5B).
However, the observed decreased Vpu antagonism of AxA is not as pronounced as that seen
with s-Tetherin. Altering the serine/threonine residues also impairs Vpu mediated particle release
(lane l-STS, top panel Figure 2-5B). However, as with the tyrosine mutations the effect seen is
intermediate between l- and s-Tetherin. A mutant that combines the tyrosine and serine/threonine
changes appears to recapitulate the high level of resistance to Vpu antagonism observed with sTetherin (lane l-SY, top panel Figure 2-5B). Thus it appears that both these regions are involved
in Vpu mediated antagonism of Tetherin function.
Although the tyrosine and serine/threonine mutants appear to similarly affect response to
Vpu antagonism and particle release, the STS mutant Tetherin protein demonstrates resistance
to Vpu-mediated degradation comparable to that of s-Tetherin (third panel, Figure 2-5). In
contrast, the AxA mutant protein levels decrease upon Vpu expression comparably to parental lTetherin (third panel, Figure 2-5).

The combined tyrosine and serine/threonine mutant (third

panel, lane l-SY) is Vpu resistant like s-Tetherin and the STS mutant. Overall, these findings
support an important role for the STS region in Vpu mediated degradation of Tetherin.
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The l-Tetherin isoform is an inducer of NF-κB
Tetherin has been primarily characterized as a cell intrinsic viral restriction factor.
However, Tetherin has been proposed to have additional activities including a role in induction of
the proinflammatory response regulator NF-κB (191).

To confirm that Tetherin was able to

activate NF-κB, a luciferase reporter assay was employed in 293T cells transiently expressing
Tetherin. Activation of NF-κB by Tetherin displays a bell shaped curve with decreased stimulation
at high levels of Tetherin expression (Figure 2-S6), suggesting an optimal range of expression for
signaling. Expression of wt Tetherin led to NF-κB activation approximately 20-30 fold over control
cells transfected with the expression vector alone (Figure 2-6A). Moreover, Tetherin activation of
NF-κB is specific since there was no effect upon AP1-regulated signaling (Figure 2-6B). TRAF6,
an ubiquitin ligase involved in regulating various signal transduction pathways including NF-κB,
upregulated both NF-κB and AP1. Supporting the specificity of the observed effect for NF-κB,
activation by Tetherin was effectively blocked in a dose dependent manner by expression of a
dominant-negative form of the NF-κB activating kinase IKKβ (DN-IKKβ, Figure 2-6C).
We next assessed whether the Tetherin isoforms had differential abilities to activate NFκB. Unlike wt Tetherin, the truncated s-Tetherin isoform displayed no NF-κB activation (Figure 26A). Conversely, compared to wild type, the l-Tetherin isoform was, on average, a more potent
activator and increased NF-κB activity approximately 40-fold over basal levels. As was seen for
wt Tetherin, NF-κB activation by l-Tetherin was sensitive to inhibition by DN-IKKβ (Figure 2-6C).
These findings demonstrate that sequences within the 12 amino acid region absent in s-Tetherin
are required for the signaling events downstream of Tetherin that activate NF-κB.

NF-κB activation requires the tyrosine motif and is negatively regulated by s-Tetherin
As described above, Tetherin can assemble into hetero and homodimers of the l- and sisoforms. Given the observations that s-Tetherin does not activate NF-κB, l-Tetherin is more
potent than wt, and wt Tetherin has an intermediate signaling phenotype to that of l- and sisoforms, we investigated whether the short isoform could modulate signaling activity of the
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longer species. To address this question, varying ratios of the two isoforms were assessed for
their ability to activate NF-κB. As seen in Figure 2-7, l-Tetherin mediated NF-κB activation is
strongly diminished by the presence of s-Tetherin. The ability of s-Tetherin to sharply reduce
signaling at a 1:1 and 1:3 ratio of l- to s-Tetherin expressing plasmids is supportive of a model in
which homo-oligomers of the longer species are needed to signal.

Overall, this observation

suggests an inhibitory role for s-Tetherin in regulating NF-κB signaling by l-Tetherin.
Within the 12 amino acids unique to l-Tetherin are two highly conserved tyrosine residues
at positions 6 and 8 (Figure 2-1). To address whether these residues contributed the ability of the
longer isoform to activate NF-κB, alanine substitution mutations were generated in the context of
l-Tetherin and tested by transient expression in 293T cells. Compared to the parent l-Tetherin, the
ability of the tyrosine mutant (AxA) to activate NF-κB was significantly reduced (Figure 2-6A).
Although impaired, a low but reproducible level of activity was observed for the dual tyrosine
mutant. These data suggest that the mutated residues form part of an important signaling motif
within the cytoplasmic tail region needed to activate NF-κB that is present only in the longer
isoform of Tetherin.
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DISCUSSION

Here we identify a previously undescribed isoform of human Tetherin generated by
translation at an in-frame initiation codon 33 nucleotides downstream of the canonical translation
start site, which results in the loss of a 12-amino-acid N-terminal sequence.

Alternative

translation initiation in eukaryotes can occur by 3 different mechanisms: internal ribosome entry,
reinitiation, or leaky ribosome scanning. Our analysis indicates that the tetherin mRNA contains a
“leaky” Kozak sequence around the first AUG codon (M1). Based on the scanning model of
translation, this would allow the ribosome to skip over the first start codon a fraction of the time,
leading to initiation at the next in frame AUG (M13). Selective disruption of each AUG and
introduction of a strong Kozak at the upstream AUG confirmed that alternate sites of translation
initiation accounted for each of the observed products. Conservation of an upstream leaky Kozak
and a second cytoplasmic methionine in most mammalian Tetherin sequences, along with our
analysis of expression from rhesus and murine cDNAs, suggests that multiple isoforms exist in
other species and indicate an important biologic role(s) for the two isoforms.
For many messages with alternatively translated isoforms the resultant proteins display
distinct functionalities (116, 130, 182, 254). This is clearly the case for Tetherin where we
identified unique biologic properties for the two isoforms. Although both isoforms exhibit antiviral
activity, the shorter Tetherin isoform, derived by initiation at M13, is highly resistant to the
antagonistic effects of HIV-1 Vpu and therefore may play a more important role in restricting virion
budding in HIV-1 infected cells. Analysis of mutants in the 12 residues unique to l-Tetherin
suggests that the combined loss of two tyrosine and three serine/threonine residues accounts for
the Vpu resistance of s-Tetherin. By contrast, l-Tetherin seems to be hypersensitive to Vpu
antagonism. However, this longer isoform possesses the ability to induce the immune response
regulatory transcription factor NF-κB while s-Tetherin does not have this capability. Expression of
the wt Tetherin cDNA, which produces both protein species yielded phenotypes for Vpu
sensitivity and NF-κB signaling that were intermediate between those seen upon expression of
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the individual isoforms. This likely reflects that fact that when the isoforms are co-expressed both
hetero and homodimers form, and that the unique properties observed (e.g. Vpu resistance and
NF-κB signaling) require short-short or long-long homodimers respectively.
In several other systems where alternative translation initiation produces multiple
isoforms there are observed differences in the ratios of the isoforms in tissues (130, 182) or under
various physiologic conditions (3) suggesting regulation of alternative initiation. For example, the
levels of glucocorticoid receptor (GR) isoforms vary significantly in different tissues, indicating that
cells can regulate this ratio with important consequences for GR gene regulation (130). Similarly,
LPS regulates differential expression of alternatively translated forms of the CCAAT/enhancerbinding trans-activator proteins C/EBPα and C/EBPβ, producing isoforms with unique properties
(3). In our experiments, the ratios of l- and s-Tetherin differed in transient expression versus
endogenous expression. Lysates harvested 48 h post-transient transfection appeared to produce
more of the longer species. In contrast, 48 h stimulation with IFN produced roughly equal
amounts of both isoforms. Interestingly, tissue specific expression of ovine Tetherin isoforms has
been reported (9); however, the mechanism for generation of these isoforms was not
investigated. Our analysis of human Tetherin did not query a large number of cell types or
conditions, therefore it will be interesting to more fully address whether there are instances in
which the ratio of l- and s-Tetherin is regulated. Conversely, the increased sensitivity of l-Tetherin
to Vpu compared to s-Tetherin suggests that viral antagonists might alter the isoform ratio.
Because both NF-κB signaling and Vpu sensitivity appear to be affected by the formation of
homodimers, this suggests a model whereby subtle changes in isoform stoichiometry, either by
differential expression or susceptibility to viral antagonists of one isoform, could rapidly and
dramatically affect Tetherin function.
The importance of the shorter Tetherin isoform with increased antiviral activity or
resistance to viral antagonists is strongly supported by recent evidence. While this manuscript
was in preparation, a polymorphic allele that abrogated expression from the first methionine
residue, and thus produced only short isoforms, was described in NZW mice. In these mice,
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expression of shorter Tetherin isoforms strongly correlated with decreased Friend retrovirus
replication and pathogenesis (17). Tetherin sequence variants have also been identified in rhesus
macaques, African green monkeys and mice (144, 261). Interestingly, none of the identified
macaque polymorphisms account for the single species we observed by Western blot in the
macaque FRhK-4 cell line. Further analysis of genomic sequence of tetherin from this rhesus cell
line is required to determine the form being expressed.
We find that the ability of s-Tetherin to retain budding HIV-1 virions and to resist Vpu
more effectively than l-Tetherin appears to be due to loss of tyrosine and serine threonine motifs
found in the cytoplasmic tail of the long isoform.

Mutation in either motif rendered Tetherin

partially resistant to Vpu. Combining these two sets of mutations recapitulated loss of Vpu
sensitivity seen for s-Tetherin suggesting these represent important differences between l- and sTetherin. The tyrosine motif in l-Tetherin is a non-canonical trafficking signal (YXYXXV) that
engages the AP-1 and AP-2 clathrin adaptors (140, 181); mutations within this sequence alter
cellular trafficking and distribution (78, 92). It has recently been demonstrated that Vpu impairs
recycling of Tetherin to the cell surface and that this is a key mechanism for antagonizing
Tetherin function (195). It will be interesting to determine if s-Tetherin effectively recycles in the
presence of Vpu or if endocytosis from the cell surface is affected. Also, within the region unique
to l-Tetherin is a serine-threonine-serine stretch that has been shown to be important for Vpu
mediated Tetherin degradation (229) although more recent studies have questioned this
conclusion (72, 229). Our finding that mutations in this motif confer partial resistance to Vpu
antagonism and also affect Vpu induced degradation support an import role for this region in
interactions with Vpu. Interestingly, particle retention and Tetherin degradation appear to be
separable features because the STS mutant appeared to be resistant to Vpu induced degradation
while the YxY mutant remained sensitive to Vpu degradation, yet both mutations partially impair
Vpu induced virion release. Our data is consistent with a model in which both decreased protein
turnover and altered trafficking account for the ability of s-Tetherin to effectively retain virions in
Vpu-expressing cells.
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The observation that the long isoform activates NF-κB while the short isoform shows no
activity suggests that sequences within the 12 residues unique to l-Tetherin mediate signaling.
Moreover, data demonstrating higher NF-κB induction by expression of the l-Tetherin isoform
compared to the wt cDNA, coupled with an inhibitory affect of s-Tetherin on NF-κB activation,
support a model in which homodimers of the longer isoform are responsible for signaling. Though
Tetherin does not possess canonical tyrosine-based motifs involved in activating signal
transduction pathways, there is evidence that dimerization of CLEC-2 allows approximation of a
non-canonical tyrosine-based motif and permits signaling via Syk kinase (87). Furthermore,
phosphoproteomic analysis has shown that Tetherin tyrosine residues at positions 6 and 8 can be
phosphorylated (211). Moreover, mutation of both these tyrosine residues greatly diminished NFκB induction, demonstrating that they are critical for this activity. Because the dual tyrosine
residues have been shown to be important in trafficking it will be crucial to assess whether
differential localization may also play a role in activating signal transduction. The ability of a
dominant negative form of the kinase IKKβ to inhibit Tetherin-induced NF-κB activity indicates
that activation likely involves the canonical pathway, however the mechanism by which Tetherin
couples to this pathway remains to be elucidated. Similarly to our findings with Tetherin, it has
recently been found that the cytoplasmic tail domain of HIV-1 envelope activates NF-κB, but not
AP1 (176). In this case activation occurs via the canonical NF-κB pathway, with HIV-1 envelope
directly engaging TGF-β-activated kinase 1 (TAK1).

Whether Tetherin utilizes a similar

mechanism to specifically activate NF-κB remains to be explored.
It has been demonstrated that Tetherin is a ligand for ILT7 on human dendritic cells and
that binding initiates signaling via the ILT7–FcεRIγ complex, inhibiting production of interferon and
proinflammatory cytokines by dendritic cells (35). It will be interesting to investigate if ILT7, or an
unknown ligand can modulate NF-κB activation by Tetherin. The viral restriction factor TRIM5α
has recently been shown to function as a unique pattern recognition receptor recognizing the
hexagonal lattice pattern of entering retroviral capsids to activate NF-κB and MAP kinase
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pathways (172). In a similar vein, we speculate that Tetherin could recognize the “pattern” caused
by budding virions to activate NF-κB.
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MATERIALS AND METHODS

Cell Culture
293T, HT1080 and HeLa cells were maintained in high glucose DMEM + 10% Cosmic Calf
Serum (Hyclone). Primary CD4 T cells (obtained from the University of Pennsylvania Center for
AIDS Research Immunology Core, ND307) were maintained in RPMI + 10% FBS (Invitrogen). All
cells were maintained at 37°C with 5% CO2.

Plasmids and Reagents
Human tetherin cDNA in pCMV-SPORT6 was acquired from Open Biosystems. Tetherin mutants
were generated using site-directed mutagenesis by PCR. Primers for site-directed mutagenesis
were designed using QuikChange Primer Design Program (Agilent Technologies). The HIV-1
gag-pol encoding construct, psPAX2 was obtained from Addgene (plasmid 12260). HIV-1 vpu
and ebolavirus GP cloned into pCAGGS were previously described (100, 204). The NF-κB
reporter plasmid, pBIIX-Luciferase was provided by Dr. Michael May (University of Pennsylvania).
The TRAF6 coding region was cloned from a cDNA (Open Biosystems) into pKMyc (Addgene
plasmid 19400) to generate an N-terminally FLAG-tagged version using an XbaI restriction site
adjacent to the FLAG-tag. The dominant negative FLAG epitope tagged IKKβ (K44M) plasmid
was obtained from Addgene (plasmid 11104). The AP1 reporter (Biomyx) and MEKK1-delta
plasmids were obtained from Dr. Sunny Shin (University of Pennsylvania).

Tetherin Protein Expression Analysis
HT1080 cells in a 6 well were transiently transfected with Tetherin expression constructs using
Lipofectamine2000 (Invitrogen) according to manufacturers instructions. For IFN induction
experiments, HT1080, 293T, HeLa and primary CD4 T cells were incubated +/- 1000U of
recombinant type I IFN (PBL Interferon Source) for 48 h. Two days post-transfection/IFN
treatment, cells were washed with PBS and lysed using RIPA buffer (10mM Tris-HCl pH 8.0,
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5mM EDTA, 140mM NaCl, 1% sodium deoxycholate, 0.1% SDS, 1% NP40). Lysates were
passaged through a 25G needle before being cleared by centrifugation at 17,900x g for 15 min at
4°C. Cleared lysates were treated with either treated or not with PNGase (New England BioLabs)
for 2 h, then reduced using DTT containing loading buffer. Samples were separated on a 15%
Criterion gel (BioRad) and transferred to PVDF membrane. After blocking in 5% milk TBST (Trisbuffered saline + 0.1% Tween), Western blots were analyzed for Tetherin expression using rabbit
anti-BST2 sera (Dr. Klaus Strebel, #11721 National Institutes of Health AIDS Research and
Reference Reagent Program).

VLP Budding Assay
5

2.5x10 293T cells seeded on a 24 well plate were co-transfected with the indicated tetherin
construct (12.5 ng), an HIV-1 Gag-Pol expression vector pSPAX (50 ng) and increasing amounts
of (25, 50 or 100 ng) of pCAGSS-vpu or pCAGGS ebolavirus GP using Lipofectamine2000. Cell
lysates and supernatants were harvested 48 h post-transfection. Cell lysates were harvested in
Triton X-100 buffer (50mM Tris-HCl pH 8.0, 5mM EDTA, 150mM NaCl, 1% Triton X-100) with
Complete (Roche) protease inhibitor cocktail. Cell lysates were cleared by centrifugation at
17,900x g for 3 min at 4°C. Supernatants containing VLPs were cleared are 1700x g for 2 min at
4°C. VLPs were subsequently purified by pelleting through a 20% sucrose cushion at 40,000 in a
TLA120.1 rotor (Beckman) for 30 min. VLPs were resuspended in PBS on ice for 3 h. Cleared cell
lysates and resuspended VLPs were separated on 15% or 4-15% Criterion gels (BioRad)
respectively before being transferred to PVDF membrane. Membranes were blocked in 5% milk
in TBST for 40 min prior to incubation with primary antibody. HIV-1 Gag p24 was detected in
Western blots for both VLPs and cell lysates using a monoclonal anti-p24 antibody (24-3,
National Institutes of Health AIDS Research and Reference Reagent Program). The GAPDH
loading control was analyzed using GAPDH antibody (Calbiochem, CB1001). HIV-1 Vpu was
detected using HIV-1 pNL4-3 Vpu antiserum (969, National Institutes of Health AIDS Research
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and Reference Reagent Program). Ebolavirus GP was detected using rabbit antiserum against
the GP1 portion of the protein (125).

Flow Cytometry Analysis of Tetherin Cell Surface Expression
5

293T cells (2.5x10 ) seeded on a 24 well plate were transiently co-transfected with 25 ng Tetherin
constructs (wt, l-Tetherin, s-Tetherin or l-AxA) and 100 ng HIV-1 vpu or ebolavirus GP. Two days
post transfection, cells were washed once with 1xPBS while on the plate. Whole cells were
removed using cold 1xPBS and the cells were split into equal aliquots used for flow cytometry
and western blot analysis. Cells used for Western blot analysis were pelleted by centrifugation
then lysed in Triton X-100 buffer. Lysates were cleared and PNGase treated prior to SDS/PAGE
Western blot analysis as described above. Cells to be used for flow cytometry were resuspended
in cold FACS buffer (1xPBS, 1%BSA + 0.05% sodium azide) and pelleted at 2150x g. Cells were
resuspended in FACS buffer + PE conjugated anti-BST2 antibody (Biolegend). After 1 h
incubation on ice, cells were washed three times with cold FACS buffer and analyzed on a FACS
Calibur (BD Biosciences Immunocytometry Systems). Data analysis performed using FlowJo
9.3.1 (Tree Star).

Luciferase Assay
5

293T cells (2.5x10 ) were seeded on a 24 well plate and the following day were transfected with
the indicated tetherin constructs (50 ng) and pBIIX-Luciferase reporter (250 ng) using
Lipofectamine2000. In experiments where the long and short isoforms were co-expressed the
total amount of tetherin expression plasmid was kept constant at 50 ng. At 30 h post-transfection,
cell lysates were harvested in Triton X-100 lysis buffer. Lysates were transferred to a black flat
bottom 96-well plate. Luciferase Assay System substrate (Promega E1501) was added to the
lysates according to manufacturers directions. Samples were analyzed in a Luminoskan Ascent
microplate luminometer (Thermo Scientific). Statistical analysis was performed using PRISM
(GraphPad).
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Supplementary Methods

Coimmunoprecipitation
293T cells were transfected with l-Tetherin FLAG and/or AU1 s-Tetherin. Cells were lysed in
RIPA buffer and cleared as described above. Lysates incubated with either anti-FLAG rabbit
(Sigma) or anti-AU1 rabbit (Bethyl Lab. Inc.) antibodies bound to Protein A Dynabeads
(Invitrogen) for 4 hours. Lysates washed three times using RIPA buffer. Beads were boiled in
RIPA+6x SDS/PAGE loading buffer for Western blot analysis. FLAG-tagged l-Tetherin was
detected using a FLAG-HRP conjugated antibody (Sigma). s-Tetherin was visualized using the
anti-AU1 rabbit antibody described above.
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FIGURES

Figure 2-1. Alignment of Tetherin sequences and comparison to a consensus Kozak
translation initiation sequence. (A) Amino acid alignment comparing the amino-terminal
cytoplasmic region of Tetherin from various mammalian species. Accession numbers- Homo
sapiens:

NP_004326, Pan

ADI58594, Macaca

mulatta:

troglodytes:

NP_001177409

ACV96781, Mus

musculus:

XP_552491, Gorilla

NP_932763

gorilla:

XP_134266, Rattus

norvegicus: NP_937767 XP_579725, Sus scrofa: NP_001155227 (CL Sequencer; 80% limit).
Highlighted conserved residues include two cytoplasmic methionine residues, M1 and M13
(arrows), and a previously characterized dual tyrosine motif (*). (B). Comparison of the nucleotide
sequences at the M1 and M13 AUGs in human tetherin mRNA to a consensus Kozak translation
initiation sequence. Important residues at the −3 and +1 to +4 positions are highlighted in bold
black text. Human Tetherin does not conform to the consensus at the −3 position. l-Tetherin and
s-Tetherin refer to proteins initiated at M1 or M13 respectively. R = Purine.
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Figure 2-2. Tetherin exists as two isoforms. (A) Alignment of the Tetherin amino acid (Black
text) and cDNA (Grey text) sequences compared to strong Kozak sequence, M1A and M13I point
mutations (highlighted in black). (B) HT1080 cells transiently transfected with Tetherin encoding
plasmids (WT, Strong Kozak, M1A, M13I or M1A+M13I) were lysed, treated with glycosidase
(PNGase) to remove carbohydrate modifications and analyzed by Western blot using a polyclonal
Tetherin antibody. l = long isoform, s = short isoform (C) Tetherin isoform expression in cell
st

lysates from IFN stimulated and unstimulated 293T (1 panel), unstimulated HeLa (2

nd

panel) and

rd

primary CD4 T (3 panel) cells. Deglycosylated tetherin profiles are compared to those from
th

transiently expressing 293T cells (4 panel). l- and s- indicate the long and short Tetherin
isoforms. Stable tetherin dimers (d) and an uncharacterized smaller molecular mass species (*)
often observed under transient transfected conditions are indicated.
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Figure 2-3. Tetherin isoforms have different sensitivities to viral antagonists. (A and B)
293T cells were transfected with a constant amount of an HIV-1 Gag-Pol expression vector, a
constant amount of the indicated Tetherin expression plasmid and increasing amounts of
plasmids expressing the viral antagonists (A) Vpu or (B) ebolavirus GP. VLPs (Top panels) from
supernatants were purified and analyzed for HIV-1 Gag p24 release. Cell lysates were probed for
cellular levels of HIV Gag and Tetherin. As in Figure 2-2C (*) indicates an undefined species
often seen upon transient Tetherin expression in 293T cells. Titration of viral antagonists was
assessed using Vpu and GP specific antibodies. GAPDH is used as a lysate loading control.
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Figure 2-4. Effect of viral antagonists on surface levels of Tetherin. 293T cells were
transiently co-transfected with the indicated Tetherin plasmids in the presence viral antagonists
Vpu or ebolavirus GP. Half the cells were analyzed by flow cytometry. Graph represents of the
mean MFI from multiple experiments (n = 5); error bars = SEM. Surface Tetherin in the absence
of viral antagonist was set to 100%. Expression of total cellular Tetherin was analyzed by
Western blot of PNGase treated lysates from cells not used for flow cytometry. Reduced
monomers, stable dimmers (d) and an unknown species (*) are indicated. Arrow indicates sTetherin isoform seen in wt+Vpu expressing cells. GAPDH used as a loading control.
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Figure 2-5. Resistance to Vpu antagonism requires mutations in the tyrosine and
serine/threonine motifs in Tetherin. (A) Amino acid sequences of l-Tetherin mutants that
disrupt the tyrosine motif (l-AxA), the serine/threonine residues (l-STS) and the combined mutant
(l-SY). (B) 293T cells were transfected with HIV-1 Gag-Pol and Tetherin expression vectors plus
increasing amounts of plasmids expressing the viral antagonist Vpu (25 or 100 ng). VLPs (Top
panels) from supernatants were purified 48 h post transfection and analyzed for HIV-1 Gag p24
release by Western blot. Cell lysates were probed for cellular levels of HIV-1 Gag and Tetherin.
As in Figure 2-2C (*) indicates an unknown species often seen upon transient Tetherin
expression in 293T cells. Titration of Vpu was detected using anti-Vpu antibody. GAPDH is used
as a lysate loading control.
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Figure 2-6. Tetherin isoforms differentially activate NF-κB. (A) 293T cells transiently cotransfected with either a wt, l-Tetherin, s-Tetherin or l-AxA encoding plasmid plus an NF-κB
responsive firefly luciferase reporter plasmid were lysed and analyzed for luciferase activity 24 h
post transfection. Myc-TRAF6 used as a positive control for NF-κB activation. NF-κB signaling
experiments (n = 8 in triplicates) were analyzed by one-way ANOVA. (B) Luciferase assay for AP1 activation was assessed as in (A) using an AP1 responsive firefly luciferase plasmid (500 ng) in
the presence of the same Tetherin encoding plasmids. MEKK1 and myc-TRAF6 were used as
positive controls for AP1 activation. AP1 signaling experiments (n = 4 in triplicates) were analyzed
by one-way ANOVA. (C) wt and l-Tetherin were co-transfected with increasing amounts of a
FLAG epitope tagged dominant negative (DN)-IKKβ and the NF-κB responsive luciferase
reporter. Myc-TRAF6 was used as a positive control (n = 3 in triplicates). Representative blot
showing expression of co-transfected constructs as well as a GAPDH loading control. On the
Western blots, as in Figure 2-2C, (*) indicates unknown species. In the graphs ns = not
significant; *** p<0.001.
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Figure 2-7. s-Tetherin modulates l-Tetherin-mediated NF-κB induction. 293T cells were
transiently transfected with an NF-κB luciferase reporter and varying ratios of l- and s-Tetherin
expression vectors with the total tetherin expression plasmids amount kept constant. Cells were
lysed and analyzed for luciferase activity. In parallel, an l:s titration (black bars) was compared to
l-Tetherin titrated with empty plasmid (white bars). wt Tetherin signaling (grey bar) was assessed
during each experimental replicate (n = 9 in triplicate). Two-way ANOVA performed to assess
statistical significance. A representative Western blot for Tetherin is shown for each set of
titrations. *p<0.05; ***p<0.001, **** p<0.0001.
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Figure 2-S1. Comparison of Kozak translation initiation sequences of mammalian Tetherin
messages. Tetherin cDNA sequences from various mammals (Ensembl Gene IDs: CpzBST2
(Chimp)-

ENSPRTRT00000019678,

GorBST2

(Gorilla)-ENSGGOT00000015329,

RhBST2

(Rhesus)- ENSMMUT00000008172, MsBST2 (Mouse)- ENSMUST00000051672; NCBI Ref
Sequence: RtBST2 (Rat)- NM_198134.1) restricted to approximately half the cytoplasmic tail and
9 bases upstream of the canonical start codon were aligned and are shown with the deduced
amino acid sequences under the corresponding codons. Matches to important residues in the
consensus Kozak sequence (−3, and +1 to +4) are denoted in black in each sequence. In all
cases, the upstream methionine deviates from the consensus at the −3 position.
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Figure 2-S2. Resolution of heterogeneous Tetherin expression profile by removal of
carbohydrate modification with PNGase. Lysates from HT1080 cells transiently expressing wt
Tetherin cDNA were prepared 48 h post transfection. Lysates were analyzed by Western blot
using a Tetherin antibody. Left panel (no PNGase), right panel (with PNGase).
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Figure 2-S3. Endogenous expression of Tetherin isoforms. IFN stimulated or unstimulated
HeLa, HT1080 and 293T cells were analyzed at 48 h post exposure. Cellular lysates were used
directly or digested with PNGase and analyzed by Western blot. A lighter exposure of PNGase
treated profile is shown below the main blot. HT1080 cells transiently expressing wt, l-Tetherin, sTetherin, l+s-Tetherin or wt Strong Kozak mutants were harvested, PNGase treated and analyzed
adjacent to endogenous Tetherin samples.
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Figure 2-S4. Expression profiles of rhesus and murine Tetherin. (A) 293T cells were
transfected with murine Tetherin cDNA. Concurrently, murine J774 cells were IFN treated for 48
h. Lysates were PNGase treated and analyzed by Western blot using an anti-mouse CD317
antibody (BioLegend, 127101). Shorter exposure of the transfected 293T cells is shown to the
right. (B) Lysates from 293T cells transiently expressing rhesus Tetherin cDNA were analyzed
adjacent to lysates of rhesus FRhK-4 cells. The right panel is a lighter exposure of the 293T lane
from the same blot. While the J774 cells, the murine and rhesus Tetherin cDNAs produce two
isoforms, only a single species that corresponds to the upper (presumably l-Tetherin) isoform is
seen in FRhK-4 cells.
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Figure 2-S5. Isoforms produce homo- and heterodimers. (A) HT1080 cells transiently
expressing Tetherin mutants form homodimers. HT1080 transfected with either wt, l-, s- or l+sTetherin were lysed in RIPA buffer. Lysates were PNGase treated for 2 h without denaturation.
Deglycosylated samples were analyzed under non-reducing conditions and probed for Tetherin
using

anti-BST2

rabbit

sera.

l:l=Long

homodimers;

s:s=short

homodimers.

(B)

Co-

immunoprecipitation of epitope tagged isoforms. Cartoon of differentially tagged l- and s-Tetherin
expression vectors with tags adjacent to the GPI anchor additions site or at the amino terminus
respectively. Epitope tagged Tetherin isoforms were transiently expressed in 293T cells then
RIPA lysates were precipitated using the indicated antibodies. Precipitates were analyzed by
SDS/PAGE and Western blot. Lane 1, mock transfected; Lane 2, wt-Tetherin FLAG; Lane 3, lTetherin FLAG; Lane 4, AU1 s- Tetherin; Lane 5, l-Tetherin FLAG+AU1 s- Tetherin.
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5

Figure 2-S6. NF-κB induction varies with Tetherin expression level. 293T cells (2×10 ) were
transiently transfected with a range of amounts of Tetherin expression plasmid (12.5, 25, 50, 100
or 200 ng) and a constant amount NF-κB luciferase reporter. Total DNA transfected was kept
constant by including empty vector. The results consistently show a bell shaped response for NFκB activation by Tetherin. From these results 50 ng was chosen as an optimal amount of plasmid
for the NF-κB activation assays. This graph is a representative experiment done in triplicate, bars
= SD
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ABSTRACT
Tetherin is a potent cellular restriction factor that directly inhibits the egress of a broad
range of enveloped viruses. Recent lines of evidence suggest Tetherin can act as a patternrecognition receptor (PRR) that upon sensing viral particle budding can mediate activation of NFκB via a non-canonical tyrosine based motif, correlating with enhanced proinflammatory cytokine
expression. Here we report that a previously described Tetherin mutant can activate NF-κB in a
tyrosine-independent fashion, via a similar pathway to wt Tetherin. Tyrosine-independent
activation requires alteration of a serine-threonine-serine (STS) motif near the amino terminus of
the Tetherin cytoplasmic tail. As previously reported, this mutant, SY Tetherin, displays Vpu
resistance. We identified minimal sequence in STS that conferred both signaling function and Vpu
resistance in the dual tyrosine mutant background, as well as additional determinants of Tetherinmediated signaling, including single point mutations that affect NF-κB activation. Introduction of
acidic residues upstream of the dual tyrosine motif abrogates NF-κB activation. Conversely,
increased hydrophobicity via bulk alanine substitution upstream of amino acid position 13 permits
signaling. Our panels of mutants provide insight into how the early steps of Tetherin-mediated
signaling may be controlled. This data suggests that the first 13 amino acids of Tetherin, unique
to the long isoform, may be regulatory, rather than involved in direct recognition of signaling
machinery through a proposed hemITAM as has been previously reported.
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INTRODUCTION

Timely sensing of and response to viral infection is crucial for maintaining host
homeostasis and survival. Pattern recognition receptors (PRRs) represent a number of innate
and intrinsic immune sensors that recognize broad pathogen associated signatures. Specific
localization of PRRs allows recognition of various virus-derived ligands, like viral proteins and
nucleic acid, at sites of entry, genome replication and/or egress. Sensing of pathogen-derived
ligands can lead to activation of various transcription factors including NF-κB, IRFs and AP1,
which regulate expression of various immune stimulatory cytokines like proinflammatory
cytokines and interferon (IFN). Cells also express specific intrinsic sensors and can upregulate
IFN-stimulated genes (ISGs) that directly block viral replication. These factors can be broadly
acting like viperin and ISG15 (155, 163, 164, 244), disrupting broadly conserved viral replication
processes or can be more specific to particular viral families, like TRIM5α, which plays a role
specifically recognizing capsid upon HIV-1 entry or APOBEC3G which interfere with retroviral
reverse transcription (137, 193, 202, 219)
The mammalian intrinsic cellular restriction factor, Tetherin (BST2, CD317, HM1.24) has
been suggested to also act as a pattern-recognition receptor (PRR), mediating-sensing of viral
assembly and budding, thus coupling its “tethering” function to its ability to activate the classical
NF-κB pathway (59, 228). Tetherin can enhance expression of NF-κB dependent proinflammatory
cytokines, like IL-6 and CXCL10 (59). IFNβ expression is enhanced in the presence of tethered
replication competent HIV-1 lacking Vpu (59) presumably from sensing of viral nucleic acids from
degraded endocytosed particles (158). Tetherin activation of NF-κB, in part, is mediated by a
dual-tyrosine motif (44, 59, 228) previously shown to also regulate Tetherin localization (140,
181). Though the non-canonical tyrosine based motif has been demonstrated to be crucial for
signaling, mutational analysis has demonstrated that additional residues in the cytoplasmic tail,
as well as residues in the transmembrane domain and ectodomain are important (25, 59, 228)
suggesting complexity to how Tetherin may be signaling. The GPI anchor has been identified as
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important (60), though there are conflicting reports (25, 228), suggesting that merely having a
second anchor may be sufficient. Though the cytoplasmic tail is important, it is not sufficient.
Swapping the human Tetherin cytoplasmic tail on other protein scaffolds, like on rhesus Tetherin,
which is signaling deficient, does not allow gain-of-function.
Tetherin is a lipid raft resident protein, which places it at the site of budding for various
families of enveloped viruses and also proximal to signaling platforms. Like many common
signaling receptors, Tetherin clustering, either antibody-mediated or by sensing a “ligand”,
activates signaling. When the cell is at rest, Tetherin is believed to interact with the actin
cytoskeleton through an actin associating GTPase activator, RICH2 (60). Upon sensing of viral
particle budding through the actin cytoskeletal network, a putative hemITAM in the Tetherin
cytoplasmic tail is phosphorylated. This event is thought to mediate recruitment of Syk kinase to
initiate NF-κB activation. Syk activation subsequently recruits complexes comprised of molecules
such as TRAF2, TRAF6, TAK1, TAB1/2 (60).
Here we describe mutations in the cytoplasmic tail of human Tetherin that allows for
tyrosine-independent activation of NF-κB. Mutational analysis demonstrates that the STS region,
upstream of the putative hemITAM, can affect NF-κB activation in manner that is sensitive to
specific substitutions. One mutant, SY, which replaces the STS sequence with alanine residues,
had previously been shown to be robustly resistant to HIV-1 Vpu both in VLP and replication
competent infection assays (44, 247). Here we show that the SY mutant can robustly activate NFκB despite the fact that both tyrosine residues are mutated. Furthermore, we demonstrate that the
SY mutant can activate the classical NF-κB pathway and can signal through similar downstream
effectors suggesting normal Tetherin mediated NF-κB activation. The mutational analysis
suggests an important role for the amino terminal, in particular the STS region, of Tetherin in
regulating NF-κB activation. Together, this work provides evidence to suggest that the dual
tyrosine motif may be an important regulatory motif rather than a hemITAM.

70

RESULTS

Identification of a tyrosine-independent, signaling competent Tetherin
We previously mapped residues in the Tetherin cytoplasmic tail that when mutated in the
l-Tetherin background, conferred HIV-1 Vpu resistance. Mutations in the dual-tyrosine motif and
an upstream serine-threonine-serine (STS) region (mutant SY, Figure 3-1A), were required to
produce the Vpu-resistant phenotype observed with s-Tetherin via VLP budding assays and more
recently during replication-competent HIV-1 infection in a T cell line (44, 247). Further
characterization of the SY mutant, generated in the l-Tetherin background, revealed that
compared to wt or long isoform (l-Tetherin) it robustly activated NF-κB independent of both
tyrosine residues via transient reporter assay (Figure 3-1A). This result was unexpected, as the
dual-tyrosine motif had previously been shown to be important for signaling (44, 59, 228). Thus
we sought to further assess the contributions of the individual tyrosine residues for NF-κB
activation..
Using site-directed mutagenesis, we generated and analyzed a panel of tyrosine mutants
including single alanine substitutions at positions 6 (Y6A) and 8 (Y8A), as well as the more
conservative phenylalanine point mutations Y6F and Y8F (Figure 3-1A). In addition we analyzed
the dual tyrosine mutations in both alanine (AxA) and phenylalanine (FxF) backgrounds.
Substitution of tyrosine at position 6 with alanine (Y6A) was sufficient to abrogate signaling, while
alanine substitution at tyrosine 8 (Y8A) had no effect on NF-κB activation. Unlike the alanine
mutant, both individual phenylalanine mutations, Y6F and Y8F are able to active NF-κB. Signaling
by FxF is reduced significantly, similar with was previously observed with alanine mutations at
both tyrosine residues (Figure 3-1A, (44, 59, 228)). As is the case for the SY mutant signaling
function is restored in the FxF background when changes to STS (STS to AAA) are made in
combination (mutant SF, Figure 3-1A). Together, these findings suggest an important, novel role
of the STS sequence in regulating signaling.
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The mutant panel above was generated in the (l-Tetherin) background with an isoleucine
substitution at position 13 (M13I). To ensure that tyrosine independent-signaling phenotype was
not dependent upon this genetic background, we engineered SY in the wt Tetherin context (WT
SY) and analyzed it for NF-κB activation. As seen in Figure 3-1B, transient expression of WT SY
activates NF-κB signaling thus confirming the results seen with in the l-Tetherin background.
Additionally, the level of activation by SY in either the wt or l-Tetherin background was constantly
higher than that of wt or l-Tetherin. (Figures 3-1A and B). Previous analyses of Tetherin-mediated
signaling demonstrated specific activation of NF-κB signaling and not AP-1 (44, 59, 228). In
agreement with this observation, the SY mutant did not activate AP-1, nor did it activate a more
complex promoter like that of IFNβ (Figure 3-1C), We decided to assess whether SY Tetherin
consistently a more robust activator of NF-κB compared to l-Tetherin over a range of transfected
plasmid. SY signaling was generally more robust than l-Tetherin (Figure 3-1D). Taken together,
we have identified changes in the amino terminal region of Tetherin that specifically activates NFκB. in a tyrosine-independent manner. With the data presented above, we raise doubt to the
importance of the tyrosine residues and their potential to act as a hemITAM in Tetherin.

SY signaling can be regulated by s-Tetherin
The basic Tetherin functional unit is thought to be a dimer, which multimerizes with other
dimeric Tetherin species to enhance signaling function. We previously observed that l-Tetherin
signaling could be downregulated by increasing amounts of s-Tetherin. We tested whether SY
signaling is dampened similarly by s-Tetherin by transient reporter assay and observed a
significant dose dependent decrease in signaling compared to decreasing SY plasmid alone
(Figure 3-2A). In the presence of added l-Tetherin, signaling remains at levels observed with SY
alone. Since we previously observed that SY activates much more robustly at lower amounts of
plasmid expression (Figure 3-1D), this suggests that SY is the functionally dominant species
compared to l-Tetherin. We have observed l-Tetherin to activate NF-κB more robustly than wt
Tetherin over a range of plasmid expression, an observation that can be explained by the
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expression of both l- and s-Tetherin off the wt plasmid (Figure 3-2B, (44)). Signaling by WT SY,
which expresses SY and s-Tetherin off the same plasmid, has reduced signaling compared to SY
alone confirming the dominant-negative effect observed when s-Tetherin is independently titrated
in (Figure 3-2B).

Identification of additional residues important for Tetherin-mediated signaling
Triple alanine scanning has been performed on the Tetherin cytoplasmic tail, identifying
runs of residues important for signaling (59). The observation that the Y6F mutant retains
signaling function, we called into question whether the dual tyrosine motif is acting like a bona
fide hemITAM. To clarify the requirement within the cytoplasmic tail we sought to identify
additional single point mutations that may regulate Tetherin signaling. We performed single
alanine scanning on the entire Tetherin cytoplasmic tail using site-directed mutagenesis and
identified four residues for which alteration to alanine significantly impair NF-κB activation. In
addition to the requirement for Y6, a significant but less dramatic effect was observed with an
alanine substitution at the threonine at position 4 (T4) (Figure 3-3A). Additionally, we confirmed
the findings that R19 is crucial, and to a lesser extent other membrane proximal basic residues
previously observed by triple alanine scanning (59). The loss/reduction in signaling for the Y6A,
R19A, and T4A mutants were confirmed by testing a range of plasmid expression compared to
the l-Tetherin parental background (Figure 3-3B). Additionally, we observed a conservative
mutation at position 2 (A2V) led to a loss of signal. However, expression of the glycosylated,
mature forms of the A2V mutant was poor with the exception potentially explaining the loss of
signaling ability (Figure 3-3C, lower panel). In contrast an acidic substitution at this position (A2E)
expresses comparably to l-Tetherin, signaling was abrogated. Combined with the finding that
alteration of the STS region can restore signaling function to tyrosine mutants, this mutational
analysis has identified an important role for N-terminal residues of the cytoplasmic tail in Tetherinmediated NF-κB activation.
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Tyrosine-independent Tetherin mutant can signal through a similar pathway as wt Tetherin
To determine if the SY mutant might provide insight as to how the amino terminal region
of the cytoplasmic tail contributes to regulation of Tetherin-mediated NF-κB activation., we first
needed to ascertain if

SY behaves like wt Tetherin. As previously observed with wt and l-

Tetherin, NF-κB activation by SY can be blocked with a dominant negative (DN)-IKKβ (Figure 34A). This demonstrates that similar to wt, SY acts through the classical NF-κB pathway Titration
of wt IKKβ, which activates NF-κB independent of Tetherin, enhanced signaling in a dose
dependent manner for wt, l- and s-Tetherin. Increasing the level of IKKβ did not increase reporter
activation with the SY mutant suggesting that robust activation observed might be saturating the
available IKKβ in complex present in the cell.
TAK1 has been found to associate with signaling competent Tetherin constructs (59,
228). We performed coimmunoprecipitation (co-IP) to assess whether TAK1 could interact with land s-Tetherin isoforms and the SY mutant (Figure 3-4B). Cell lysates containing transiently
expressed proteins were immunoprecipitated using an anti-Tetherin Ab. As expected, TAK1 was
found to associate with wt Tetherin. Both l-Tetherin and SY pulled down TAK1 while the
signaling-deficient s-Tetherin, did not associate with TAK1. The ability of the AxA mutant in the lTetherin background to precipitate TAK1 was highly variable across multiple experiments.
Tetherin has been suggested to mediate signaling via a hemITAM motif that directly
recruits Syk kinase (60). We sought to determine whether SY was still Syk dependent. 293T cells
transiently transfected with Tetherin mutants and NF-κB reporter were treated for 18h with a Srcfamily inhibitor, Piceatannol, or a Syk-kinase specific inhibitor, BAY61-3606. Both resulted in a
dose dependent decrease in SY-mediated signaling (Figure 3-4C) suggesting Src- and Syk-family
kinases are required for signaling. Taken together, SY appears to utilize similar downstream
effectors to wt Tetherin for NF-κB signaling function.
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Ebolavirus glycoprotein antagonizes the SY mutant tethering function
We previously demonstrated that the ebolavirus glycoprotein (EBOV GP) can counteract
l- or s-Tetherin equally well to relieve tethering of HIV-1 virus-like particles (VLPs) (44). This
agrees with the current model of how EBOV GP may be counteracting Tetherin that suggests a
mechanism of action that is cytoplasmic tail independent (126). In contrast to the Vpu resistance
observed above, the SY mutant is effectively antagonized with increasing amounts of EBOV GP
as determined by efficient VLP release (Figure 3-5, VLP panel). Total Tetherin levels remain
unchanged as previously observed with other Tetherin constructs tested. Additionally, all forms of
Tetherin tested are incorporated equally well into VP40 VLPs (Figure 3-5, VLP panel), confirming
a recent observation suggesting that mechanistically EBOV GP may counter Tetherin by allowing
incorporation into particles (71). Thus SY Tetherin appears to be resistant to Vpu but not EBOV
GP mediated antagonism.

Minimal changes in STS that confer signaling phenotype in tyrosine mutant Tetherin
The SY mutant includes alanine mutations in the STS residues upstream of the dual
tyrosine motif. Triple alanine scanning mutational analysis by the Neil group showed that this
mutation did not affect signaling in the wt Tetherin background (59), although we observe
reduced NF-κB activation in the l-Tetherin background (Figure 3-1A). To identify the requirements
within the STS region that confers a signaling phenotype mutational analysis was performed in
the AxA background. These studies revealed that the threonine residue at position 4 (T4) is
critical to confer NF-κB activation in the AxA background. The level of activation is comparable to
the SY mutant when T4 is changed alone or in combination with the two other residues in the
motif (S3T4AxA or T4S5AxA) (Figure 3-6A). Alanine mutations in either serine alone, S3 or S5,
modestly increases NF-κB activation compared to the AxA mutant (Figure 3-6A) but never to the
level observed with the SY mutant.
In addition to the observed effects on NF-κB activation, the changes in SY mutant also
make Tetherin highly resistant to HIV-1 Vpu (44). To determine if the individual or combined
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mutations in the region also affected Vpu-sensitivity the STS region mutant panel was analyzed in
a transient budding assay. We observed that rescue of signaling function correlated with
resistance to increasing amounts of HIV-1 Vpu (Figure 3-6B). Taken together, though the T4
mutation in the context of l-Tetherin has a modest effect on signaling (Figure 3-3A), it appears to
play an important role in allowing signaling function in the AxA background. Furthermore,
mutation in T4 synergizes with AxA to enhance resistance to Vpu.

Assessing the plasticity of STS region to mutation
Single alanine substitutions in the STS demonstrated that only residue T4 decreased wt
Tetherin NF-κB activation levels. To more thoroughly assess the role of this region in signaling
more disruptive mutations were generated into this region. Substitutions introducing acidic
residues at S3 and T4 abrogated signaling, while activation levels were diminished by an acidic
mutation at S5 (Figure 3-7A). A triple acidic mutation at STS (DED) also does not signal and
cannot compensate for the loss of the dual-tyrosine motif (DEDAxA) (Figure 3-7A). In general, we
observed that acidic residues upstream of the dual-tyrosine motif disrupt signaling, which may
explain why the A2E mutant does not signal (Figure 3-3C).
The STS region appears to have evolved in primates. Chimp and rhesus sequence from
the homologous region, STL and PIL respectively have been recently demonstrated to have
differential effects on signaling in the wt Tetherin background (60). We confirmed these findings in
the l-Tetherin background. The chimp sequence STL (ChSTL) activated NF-κB to a level that as
similar to the SY mutant and greater than the l-Tetherin parental background.

This is in

agreement with data showing that the ChSTL substitution appeared to induce greater NF-κB
activation in the wt background (60). Introduction of rhesus sequence PIL (RhPIL) abrogates
signaling. When analyzed in combination with the AxA mutation, the chimp S5L mutation can
rescue signaling, while the rhesus sequence PIL does not (Figure 3-7B),
The SY mutant carries five alanine substitutions within the amino-terminal 12 residues of
the cytoplasmic tail – the region unique to signaling competent l-Tetherin. To determine if there
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are additional specific sequence requirements needed to maintain signaling function, the
remaining residues in the cytoplasmic tail upstream of position 13 were analyzed by alanine
substitution mutagenesis. The additional alanine substitutions were placed in the context of the
SY mutant (Figure 3-7C) and analyzed by transient expression. Sequential alanine substitutions
throughout the entirety of the region unique to l-Tetherin did not disrupt signaling function (Figure
3-7C). Indeed a mutant (Ala11) in which residues 2 through 12 are all alanine induces NF-κB
activation similarly to SY mutant. Although the region unique to l-Tetherin, in particular the STS
region, is an important determinant for regulating Tetherin-mediated NF-κB activation these
results suggest a specific sequence dependent interaction with signaling machinery may occur
elsewhere on Tetherin which raises questions about the nature of the dual-tyrosine motif and
whether it acts as a hemITAM.
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DISCUSSION
In this work, we utilized a series of mutations to highlight a region in the cytoplasmic tail
of Tetherin that appears to be involved in activation of NF-κB signaling. Specifically, mutations
identified in a serine-threonine-serine (STS) region near the amino terminus causes Tetherin to
signal independently of the dual-tyrosine motif. We previously described this mutant, SY, with
changes in both tyrosines and alanine substitutions at all three residues in the STS region as
highly resistant to HIV-1 Vpu (44). Here we find that these same changes are associated with
high levels of NF-κB activation. Similarly to wt Tetherin, the SY mutant is inhibited by coexpression of the signaling-deficient s-Tetherin. The cellular requirements for SY mutantmediated signaling appears to be analogous to what has been described for wt Tetherin, in that
the classical NF-κB pathway is used and activation is dependent on Syk kinase (44, 59, 60, 228).
However, the fact that signaling occurs in the absence of tyrosine residues is inconsistent with the
current hemITAM model for Tetherin-mediated activation ((60), Figure 3-2).
Further analysis revealed that when coupled with a dual tyrosine substitution at positions
6 and 8, the threonine at position 4 (T4) within the STS region is critical for Vpu resistance and
NF-κB activation. The flanking serine residues appeared to modestly contribute additional
resistance to Vpu-mediated antagonism in the presence of T4A (Figure 6B) although there is little
effect on virion release and NF-κB activation. The STS region was previously identified, including
work from our own group, as being important for Vpu-mediated downregulation of Tetherin (44,
229). It has been suggested the STS region can be ubiquitinated in the presence of Vpu, though
this observation remains controversial (72, 228). It is unclear to what extent this STS region can
be post-transnationally modified in the absence of Vpu, if at all. Modifications like phosphorylation
or acetylation could inhibit signaling function as observed with our acidic substitutions.
Furthermore, a modification(s) proximal to the dual tyrosine motif could sterically affect tyrosine
phosphorylation in the wt or l-Tetherin backgrounds as well as potentially disrupt functions like
such as sorting or protein stability, which could be important for optimal signaling function.
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The various mutations introduced upstream of the dual-tyrosine motif in the STS region
suggest some structural specificity associated with signaling function. The STS region, which
appears to have been under selective pressure in primates, is not tolerant of acidic mutations. By
contrast, the hemITAM of CLEC-2 is preceded by a similar tri-acidic (DED) sequence that is
crucial for hemITAM signaling and triple alanine substitution abrogates its function (88). We
observe the opposite effect, where hydrophobic/nonpolar residues appear to be favored in the
presence or absence of the dual-tyrosine motif (Figure 3-1A and 3-6). The polyalanine mutations
are interesting because these substitutions abrogate any potential motif upstream of residue 13
and suggest that this region serves as a regulatory motif and not a direct protein-docking site.
Additionally, the propensity for this region of the cytoplasmic tail to form a longer hydrophobic,
coiled structure also increases. The introduction of a leucine (S5L) from the chimp sequence
does not abrogate signaling when the tyrosines are present. In fact, this substitution slightly
increases NF-κB activation in the wt (87) or l-Tetherin background and restores signaling to the
dual tyrosine mutant. This observation further supports the hypothesis that signaling is favored by
hydrophobicity in this region [leucine is one of the most hydrophobic amino acids by hydropathy
scoring (110)]. Introducing rhesus Tetherin sequence (PIL) abrogated signaling possibly due to
addition of a helix-disrupting proline that might abolish a required structural feature. Supporting
the theory that signaling may bot require a tyrosine-based motif is the recent observation that
equine Tetherin activates NF-κB when expressed transiently in human cells (259). Both equine
Tetherin proteins have a very short cytoplasmic tail with no tyrosine and no discernable signaling
motif. Interestingly, both equine Tetherin proteins contain glycines as the second amino acid
suggesting a potential myristoylation site. It is tempting to speculate that a hydrophobic
modification of the equine Tetherin amino terminus could behave similarly to hydrophobic
mutations we have analyzed in human Tetherin to promote NF-κB activation.
Single-alanine scanning within the l-Tetherin background reveals that residues Y6 and
R19 are also critical for Tetherin activation of NF-κB in agreement with previous results (59). We
identified the alanine residue at position 2 (A2) to also be important for NF-κB signaling. Because
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the second codon is important for translation initiation (+4 position of the Kozak sequence), we
designed and generated mutations that would maintain the integrity of the Kozak sequence.
Although reduced expression of the A2V mutant, possibly due to protein stability, may explain
why this mutant does not activate NF-κB, the A2E substitution is stable and does not signal. As
discussed above for the adjacent STS region, the introduction of an acidic substitution upstream
of the dual-tyrosine motif may not be compatible with Tetherin signaling function. Finally we found
that the single alanine point mutations at residue 4 (T4A) in the context of the l-Tetherin
background constantly reduced the level of NF-κB activation. The importance this residue was
likely not uncovered in previously reported triple alanine scanning experiments because, as we
have observed, runs of hydrophobic residues upstream of the dual tyrosine motif have no effect
on signaling.
The Vpu-resistance phenotype of the SY mutant that we first observed using a VLP
budding assay has since been documented in the context of replication competent HIV-1 (247).
However, Vpu from different SIVs and different HIV-1 groups, with the exception of M, have been
shown to be more indiscriminant about downregulating s-Tetherin (247), suggesting that SY could
be equally sensitive. The dual tyrosine to phenylalanine mutant, SF, which we also show can
signal, but not to the degree of SY (Figure 3-1A), has also been tested with live HIV-1, and has
been demonstrated to be Vpu-sensitive (247). This is most likely due to impaired trafficking
observed in the AxA mutant since bulky phenylalanines can potentially substitute for tyrosines in
clathrin-mediated trafficking motifs that interact with AP-2 (249). We hypothesize SY is stable on
the cell surface, as has been demonstrated with dual-tyrosine mutants and suggested for sTetherin which lacks the endocytosis motif entirely. Perhaps surface stability allows for some
increased degree of clustering, leading to the enhanced signal observed by SY over both wt and
l-Tetherin (Figure 3-1D). Surface stability may also partially explain resistance to Vpu, which is
thought to interact with Tetherin in the TGN (52).
Tetherin is hypothesized to signal via a non-canonical tyrosine based motif, most likely a
hemITAM motif (60). This motif has been identified in a number of proteins that act as immune
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receptors.

Unlike traditional ITAMs, which have interspaced phosphotyrosines, hemITAMs

contain of single phosphotyrosine and interact with signaling kinases trough dimerization. For
example, CLEC-2 hemITAM dimerization allows binding to Syk via a hemITAM through an
unconventional SH2-mediated interaction across single phosphotyrosines residues on adjacent
CLEC-2 molecules (87). Unlike a previously described Y6A mutation, which abrogates signaling,
we observed that Tetherin mutants with conservative phenylalanine mutations (Y6F, Y8F)
activate NF-κB . This is stark contrast to other described hemITAM containing proteins where
phenylalanine substitutions typically abrogate signaling (210, 262). While it is possible that our
results can be explained by theorizing that Y6 and Y8 function as redundant, overlapping
hemITAM-like signaling motifs, there is no precedent for this arrangement. Moreover, the ability of
the SY mutant, which contains no tyrosine residues in the cytoplasmic tail, to interact with TAK1
by co-IP and signal is a Syk-dependent manner supports a model that does not involve a direct
hemITAM-mediated interaction on the Tetherin cytoplasmic tail for signaling function.
Whole cell phophoproteomic analysis demonstrated that Tetherin is phosphorylated at Y8
and Y6+8 in combination (211) Interestingly no peptide containing only phoshphorylated Y6 was
identified, yet our analysis and that of Galao et al. suggest that Y6 is an important residue for wt
Tetherin signaling, it may be specifically dependent on viral particle sensing. The model for
Tetherin-mediated signaling through a hemITAM motif has been built, in part, around
immunoprecipitation of Tetherin with anti-phosphotyrosine antibodies (Abs), which correlated with
signaling function. There are some inconsistencies observed with this model.

The Y8A mutant,

which retains transient signaling function, was shown to IP with a phosphotyrosine Ab only during
MLV infection and not during transient expression (60). Additionally, triple alanine scanning
mutagenesis of regions overlapping Y6 only (TSY or SYD mutated to AAA) all retained signaling
function (59), paralleling what we have seen with the STS mutation data described above. One
hypothesis that fits with our data is that Tetherin phosphorylation specifically, rather than
recruitment of Syk directly, induces or stabilizes a conformational change in the cytoplasmic tail
important for signaling, and downstream recruitment of Syk kinase by another protein. Tetherin is
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a lipid raft resident protein and there are numerous examples of proteins that are solely GPIanchored that propagate signals into the cell, including receptors involved in immunity. However,
Tetherin uniquely contains a cytoplasmic tail in addition to the GPI anchor. Our observation that
cytoplasmic tail mutations at the amino terminal end can affect signaling suggests that region of
the tail, could act as a regulatory domain.
One aspect of SY mutant-mediated signaling that needs to be explored is whether viral
particle budding enhances activation of NF-κB . When the cell is at rest, Tetherin is believed to
interact with the actin-binding protein RICH2 via its cytoplasmic tail. The current tyrosine-based
signaling model suggests that upon actin-dependent activation by, for example, viral budding, an
unknown Src-kinase is thought to phosphorylate the Tetherin cytoplasmic tail, which recruits Syk
(Figure 3-2). The interaction with RICH2 does not appear to depend upon the dual tyrosine motif
as this mutant appears to associate with RICH2 comparably to wt Tetherin as measured by co-IP,
(60). We propose that RICH2 interaction remains intact with SY Tetherin as the association does
not appear to be tyrosine dependent. If viral particle budding enhances SY signaling, we would
hypothesize that src kinase-mediated tyrosine phosphorylation would occur on a currently
unknown signaling protein that may associate with Tetherin via another domain.
The ability of src-family and Syk specific inhibitors to impair Tetherin mediated suggests
the possibility that the compensatory changes bypass Src-mediated phosphorylation of Tetherin.
SY, and signaling competent variants that do not have tyrosines, could already be primed to
signal. In this model Syk recruitment would be through an indirect mechanism and not through a
hemITAM on Tetherin, but rather some other phosphorylated protein. We observe SY Tetherin
can interact with TAK1. One possibility is that sequence downstream of M13 can bind another
effector as long as there is scaffolding or regulatory sequence upstream. As previously stated, a
conformational change in the tail could facilitate this interaction. Alternatively, Syk could bind an
adaptor that interacts with Tetherin via the GPI anchor. GPI-anchored proteins can propagate
signals into the cell though they do not span into the cytosol. This occurs through interactions via
adaptor proteins. GPI anchored proteins cross-linked with mAb are frequently observed to be
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associated with Ca

2+

bursts and tyrosine phosphorylation (84). Interestingly, Tetherin mediated

signaling has been suggested to involve Ca

2+

as it can be dampened with BAPTA treatment

(228). s-Tetherin which has an intact GPI-anchor does not signal; this again raises the possibility
that the cytoplasmic tail could primarily play a regulatory function. Interestingly, we, and others,
have now shown Tetherin and other signaling competent mutants can interact with TAK1 (Figure,
3-4, (59, 228). The activation of the B cell receptor depends on TAK1 to mediate NF-κB signaling.
As previously mentioned Ca

2+

flux though previously implicated in ER stress (228) could be the

result of PLCγ activation via Tetherin leading to NF-κB activation. Future experiments will begin to
address whether other additional domains mediate interactions that are necessary for Tetherin
signaling function.
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MATERIALS AND METHODS

Cell Culture
293T cells were maintained in DMEM + 10% Fetal Bovine Serum (Hyclone) at 37°C with 5%
CO2.

Plasmids and Reagents
Human tetherin cDNA in pCMV-SPORT6 was acquired from Open Biosystems. All Tetherin
mutants tested were generated in the l-Tetherin (M13I) background using Change-IT site-directed
mutagenesis by PCR. Primers for site-directed mutagenesis were designed using QuikChange
Primer Design Program (Agilent Technologies). The HIV-1 gag-pol encoding construct, psPAX2
was obtained from Addgene (plasmid 12260). The pCAGGS ebolavirus FLAG-VP40 plasmid
used is previously described (100). HIV-1 Vpu and ebolavirus GP cloned into pCAGGS were
previously described (100, 204). The NF-κB reporter plasmid, pBIIX-Luciferase was provided by
Dr. Michael May (University of Pennsylvania). The TAK1 constructs were obtained from Open
Biosystems and cloned into pCMV-SPORT6. The wt and dominant negative (K44M) FLAG
epitope tagged IKKβ plasmid was obtained from Addgene (plasmid 11104). The AP1 reporter
(Biomyx) and MEKK1-delta plasmids were obtained from Dr. Sunny Shin (University of
Pennsylvania). The Sendai virus stock and IFNβ reporter were provided by Dr. Carolina Lopez .
Transfections were performed using 2.5ul of a 1ug/mL working stock of polyetheylenimine (PEI)
per 1ug DNA.

VLP Budding Assay
5

2.5x10 293T cells seeded on a 24 well plate were transfected with PEI at the described working
concentration listed above. Indicated tetherin construct (50 ng) was co-transfected with either:
Gag-Pol expression vector pSPAX (200ng) and increasing amounts of (50 or 200 ng) of
pCAGSS-vpu for HIV-1 VLP assays or pCAGGS FLAG-VP40 (100ng) and increasing amounts of
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(50 or 200 ng) pCAGGS ebolavirus GP for EBOV VLP assay. Cell lysates and supernatants were
harvested 48 h post-transfection. Cell lysates were harvested in Triton X-100 buffer (50mM TrsHCl pH 8.0, 5mM EDTA, 150mM NaCl, 1% Triton X-100) with Complete (Roche) protease
inhibitor cocktail. Cell lysates were cleared by centrifugation at 17,900x g for 3 min at 4°C.
Supernatants containing VLPs were cleared are 1700x g for 2 min at 4°C. VLPs were
subsequently purified by pelleting through a 20% sucrose cushion at 40,000 in a TLA120.1 rotor
(Beckman) for 30 min. VLPs were resuspended in PBS on ice for 3 h. Cleared cell lysates and
resuspended VLPs were separated on 15% or 4-15% Criterion gels (BioRad) respectively before
being transferred to PVDF membrane. Membranes were blocked in 5% milk in TBST for 40 min
prior to incubation with primary antibody. HIV-1 Gag p24 was detected in Western blots for both
VLPs and cell lysates using a monoclonal anti-p24 antibody (24-3, National Institutes of Health
AIDS Research and Reference Reagent Program). The loading control used across experiments
was αtubulin, which was analyzed using αtubulin mAb (12G10). HIV-1 Vpu was detected using
HIV-1 pNL4-3 Vpu antiserum (969, National Institutes of Health AIDS Research and Reference
Reagent Program). Ebolavirus GP was detected using rabbit antiserum against the GP1 portion
of the protein (125). Tetherin expression was assessed using rabbit anti-BST2 sera (Dr. Klaus
Strebel, #11721 National Institutes of Health AIDS Research and Reference Reagent Program).

Luciferase Assay
5

For single concentration assays: 293T cells (2.5x10 ) were seeded on a 24 well plate and the
following day were transfected with the indicated tetherin constructs (50 ng) and pBIIX-Luciferase
reporter (200 ng) using PEI. Total DNA was kept constant using empty pCMV-SPORT6 vector.
At 30 h post-transfection, cell lysates were harvested in Triton X-100 lysis buffer. Lysates were
transferred to a black flat bottom 96-well plate. Luciferase Assay System substrate (Promega
E1501) was added to the lysates according to manufacturers directions. Samples were analyzed
in a Luminoskan Ascent microplate luminometer (Thermo Scientific). Statistical analysis was
performed using PRISM (GraphPad).
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Co-immunoprecipitation
6

1.4x10 cells were seeded on 6 well plate. Following day (~20h), PEI transfection performed on
cells using 500ng of the indicated Tetherin constructs per well (wt, l-, s-, AxA, SY) + 500ng
pCMV-SPORT6 TAK1. Control well with TAK1 and wt Tetherin alone done in parallel, with DNA
normalized using empty pCMV-SPORT6. 18h post transfection, cells were lysed on ice for 20min
in TritonX-100 buffer in the presence of freshly added Complete (Roche) protease inhibitor
cocktail and 1mM sodium orthovanadate (NEB). Lysates were cleared for 10min at 4°C. Aliquot
of lysate set aside for input. Remaining lysate incubated with 1.5µg anti-Tetherin Ab (RS39E).
Abs and lysate incubated at 4°C while rocking for 2h after which washed Protein G Dynabeads
(Invitrogen) were added for an additional 1h. After incubation, lysates/bead/Ab complex pulled
down over chilled magnet and washed gently 4x using TritonX-100 buffer removing from magnet
each time. Protein immunoprecipitated on beads were treated with PNGase via manufacturers
instructions then boiled in 1x SDS/PAGE loading buffer for Western blot analysis. Loading control
for inputs was determined using αtubulin (12G10) Ab. TAK1 blotted for using TAK1 (D94D7)
specific Ab (CST, #5206). Tetherin blotted for using anti-BST2 sera described above.
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Figure 3-1. Identification of a signaling-competent, tyrosine-independent Tetherin. 293T
cells were cotransfected with 50ng of various Tetherin constructs and 200ng of firefly luciferase
reporter. Cells were harvested 24h post transfection for luciferase readout (A) Tetherin cartoon
with alignment of mutants generated in l-Tetherin background tested in panel assessing the
signaling ability of various tyrosine mutants. Tetherin constructs were cotransfected with pBIIXLuc for NF-κB activation. Values normalized to l-Tetherin background set to 1 (grey dotted line).
Graphs represent experiments done in triplicate (n=4); error bars= SEM *p<0.05(B) Alignment of
mutants generated in the wt Tetherin background. Tetherin constructs were cotransfected with
pBIIX-Luc for NF-κB activation. Graph normalized to wt Tetherin background set to 1 (grey dotted
line). Graph represents experiments done in triplicate (n=3); error bars= SEM ** p<0.01,
****p<0.0001 (C) l-Tetherin and SY cotransfected with either AP1 reporter (left) or IFNβ reporter
(right). Reporter activation controlled for using MEKK1 for AP1 and incubation with Sendai virus
for IFNβ. Graphs are representative of multiple experiments done in triplicate; error bars=SD.
Representative lysates ran under denaturing conditions blotted for Tetherin and GAPDH as
loading control. (D) Increasing ramp of Tetherin plasmid (12.5ng, 25ng, 50ng, 100ng and 200ng)
were cotransfected with pBIIX-Luc for NF-κB activation. Graph is a representative of multiple
experiments done in triplicate.
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CHAPTER 4: GENERAL DISCUSSION AND FUTURE PERSPECTIVES
Summary and perspectives on Tetherin isoforms
In this dissertation, we have elucidated novel biology for the cellular restriction factor,
Tetherin. A large body of research has focused on various facets of how Tetherin restricts
enveloped virus budding, which includes characterization of structural determinants necessary for
tethering function, identification of viruses that are Tetherin-sensitive and whether these viruses
encode a Tetherin antagonist, and determining, mechanistically, how virally encoded antagonists
counter Tetherin-mediated restriction (See Chapter 1). Tetherin has a short cytoplasmic tail,
which is dispensable for tethering viral particles, though it can be targeted directly by virally
encoded antagonists for downregulation to allow efficient viral replication. Aside from a tyrosinebased endocytic motif, a second cytoplasmic methionine, downstream of the putative start codon,
is highly conserved among Tetherin orthologues.
In Chapter 2 we determined that the nucleotide sequences surrounding the downstream
cytoplasmic methionine codon was in an appropriate genetic context to act as a potential
alternative start codon. Additionally, we observed that the putative primary start codon was in the
context of a suboptimal Kozak sequence (Figure 2-1B) suggesting potential ribosomal leakage.
The pre-initiation ribosomal complex composed of the 40S ribosome and Met-tRNA scan AUG
codons in this Kozak context and rather than initiate translation, skip over the potential start site a
fraction of the time (108). wt Tetherin cDNA with the endogenous Kozak sequence produces two
species: l-Tetherin, which is considered full-length expressing off the upstream open reading
frame (uORF), and s-Tetherin, which expresses off an in-frame ORF located 12 codons
downstream of the putative start site. Resolution of these species by immunoblotting is enhanced
by PNGase treatment of N-linked glycans that produce a diffuse, 30-36kDa banding pattern for
“mature” Tetherin. Interestingly, deglycosylated Tetherin blots had been analyzed prior to our
work, including one, which identified the presence of a two species in HeLa cells. However, the
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bands were misidentified as potential differences in post-translational modifications (6). It is
peculiar that the human Tetherin isoforms were not discovered previously. However, it is very
likely that prior to our study most labs did not routinely deglycosylate lysates when expressing
Tetherin and/or used Tetherin expression vectors with either strong Kozak sequences at the first
start site or codon optimized cDNA. These reasons would account for why this phenomenon was
not observed. Strengthening the Kozak upstream of the putative AUG leads to almost exclusive
expression of l-Tetherin, suggesting alternative translation initiation off a single polycistronic
mRNA as the underlying mechanism. This presents a way by which Tetherin expression, and
subsequent function(s), can potentially be modulated raising the question of whether endogenous
expression of the isoforms can be regulated by different stimuli. Additionally, the heterogeneity in
Tetherin glycosylation may be a representation of variants that could also have different cellular
localizations; changes in Tetherin glycosylation has been shown to impact subcellular
localization, but still allow restriction of certain viruses.
We expanded our observation to rhesus and murine Tetherin, also observing multiple
Tetherin species from cDNA expression further suggesting this is a conserved mechanism by a
variety of mammalian species. Mounting evidence suggests the translation of a truncated
regulatory Tetherin isoform is common in mammals. During the preparation of the work
highlighted in Chapter 2, a naturally occurring polymorphism in the putative Tetherin upstream
start codon was observed in a NZW mouse leading to expression of only the shorter isoform
lacking the dual-tyrosine motif (17). As observed in human Tetherin, loss of the tyrosine motif
stabilizes the protein at the plasma membrane. In a viral challenge experiment with Friend
retrovirus, the polymorphism conferred increased protection to viral replication compared to a B6
mouse encoding the wt tetherin sequence (17). The genomes of ruminants have been found to
have gene duplications in Tetherin, generating proteins with tails of variable length, including loss
of the conserved tyrosine residues. When tested against ovine or bovine specific viruses, the
shorter forms were the more potent antiviral product (9, 225). Additionally, feline Tetherins have
been described to have full-length and truncated tails although in the context of feline viruses
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tested, no differences in resistance to viral challenge have been observed (50, 58). Tetherin
isoforms identified thus far vary in surface stability, sensitivity to different viral antagonists and to
differentially signal. It will be interesting to determine whether there are additional functional
differences between the human Tetherin isoforms. The observation that various mammals can
express different Tetherin species suggests an underappreciated versatility of the protein. A
Tetherin-like molecule expressed in Chinese hamster cells called GREG (Golgi-resident GPIanchored protein) was shown to be involved in regulating Golgi integrity (123), a function similar
to that of Golgins, which like Tetherin are also integral membrane coiled-coil proteins. This
molecule resides almost exclusively in intracellular compartments, but is involved in impacting
membrane dynamics, which may parallel what Tetherin does at the cell surface when enveloped
viruses perturb membrane integrity.
The dual-tyrosine is important for Tethering trafficking (140, 181). There is evidence of
enhanced plasma membrane stability of Tetherin species that lack this motif in vitro, as well as in
a naturally occurring mutation in NZW mice (26). These shorter Tetherin variants may be the
most important form for restricting viral replication, which may explain why the second
cytoplasmic methionine is highly conserved. The lack of the dual tyrosine motif in s-Tetherin
makes it highly resistant to HIV-1 Vpu, which is thought to engage Tetherin intracellularly.
Conversely, l-Tetherin is highly sensitive to Vpu-mediated downregulation. Along with the dual
tyrosine motif, an upstream STS sequence, when mutated in combination produces s-Tetherinlike, Vpu resistance in the Vpu-sensitive l-Tetherin background. Independently, both these amino
terminal regions confer some degree of resistance to HIV-1 Vpu in virus-like particle (VLP)-based
systems and subsequently validated with replication competent HIV-1 (247). In the context of viral
infection, the dual-tyrosine may serve a regulatory purpose and therefore expression of full-length
Tetherin (l-Tetherin) may be important to properly traffic and relocate the short form after viral
particle restriction.
In Chapter 3 we identify the minimal mutations necessary to confer HIV-1 Vpu
resistance, highlighting a crucial threonine at position 4 (T4). Based on our data, the flanking
97

serine residues, contribute minimally to the phenotype observe with SY. It is unclear what role
these residues play in regulating Tetherin function. Ubiquitination of this motif has been
suggested in the presence of Vpu, but that mechanism remains controversial (72, 229). However,
this does not rule out the possibility of additional post-translational modifications, as serines and
threonines can be phosphorylated and acetylated. We also do not know whether these residues
contribute to trafficking. Because of the proximity between STS and the dual tyrosine motif,
modifications at either serine or the threonine could sterically hinder machinery engaging the
tyrosine residues. Phosphoproteomics has produced evidence of tyrosine phosphorylation of the
Tetherin cytoplasmic tail (211). A similar mass-spectrometry approach could be employed to
assess serine/threonine modifications, which may highlight a novel regulatory mechanism for
Tetherin function.
Co-expression of s-Tetherin affects l-Tetherin sensitivity in the presence of Vpu and
signaling function (see below), suggesting s-Tetherin has a dominant phenotype, highlighting a
potential regulatory role for this novel isoform. Alternative translation initiation of an in-frame
polycistronic mRNA generating a truncated isoform with “dominant-negative” properties was
recently described with another immune factor, mitochondrial antiviral-signaling protein (MAVS)
(30). The IFN response to viral infection is rapid and crucial for a robust innate immune response.
It is defined by the upregulation of a large array of genes collectively called ISGs. It is estimated
that our genome encodes over 300 ISGs with diverse cellular localizations and functions.
Diversification of ISGs through various transcriptional and translational mechanisms enhances
the functional repertoire of proteins to counter a myriad of viruses that could infect the host. To
date the subset of immune genes identified and validated as being regulated by alternative
translation initiation is small including Tetherin, MHC class II invariant chain (220), MAVS (30)
and osteopontin (203). The ribosome profiling analysis that identified MAVS isoforms also
identified potential internal translation initiation sites (TISs) for several other ISGs (30) suggesting
the use of isoforms with differential or regulatory biologic activities may be a common strategy
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during innate immune responses. Future studies of these putative isoforms should reveal if this is
the case.
Expression off polycistronic mRNA is not a new concept, rather an underappreciated
mechanism of regulating protein expression and diversity. Advances in sequencing technology
have furthered our understanding of how prevalent this mechanism may be. Ribosomal
footprinting assays have revealed that between 50-65% of transcripts contain more than one
candidate TISs (34, 90, 119). However, few examples of in-frame polycistronic mRNAs have
been identified and validated. Ribosome footprinting identified ribosome association with in-frame
downstream AUGs predicted to produce an alternative Tetherin isoform in both human and
murine cells, supporting our hypothesis (30, 90). Despite the footprinting studies in cultured cells
the primary TIS for Tetherin remains unclear. Expression of truncated forms of Tetherin lacking
the upstream dual tyrosine motif has been observed in sheep, cats, and mice (9, 17, 26, 37).
Moreover, most upstream sequences tend to be in the context of a suboptimal Kozak. A more indepth analysis using ribosomal footprinting on a broad range of cell types should be employed to
address whether there is preferential ribosomal binding at either start codon..
It is still unclear how, or if, Tetherin isoform expression is regulated. We don’t know
whether there is cell-intrinsic machinery that allows one isoform to be preferentially expressed in
one cell type versus another or if the isoforms are differentially translated under varying
conditions. We observed that interferon alpha (IFNα) stimulation appeared to upregulate both
isoforms equally in several cell types/lines tested, including 293T, HT1080, HeLa and primary
CD4 T cells although these studies did not employ stringent quantification. It is unknown whether
tetherin mRNA can form secondary structures, like hairpins, around the start sites, which could
regulate initiation/scanning of the pre-integration complex and/or processivity of the 80S ribosome
leading to differential protein expression.
A common consequence of innate response to viral infection is global repression of
translation by the host cell. This mechanism is highly effective against various viral families that
replicate in the cytoplasm. During periods of stress eukaryotic translation initiation factor 2 (eIF2)
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becomes phosphorylated by one of four known kinases, one of which is the IFN induced viral
RNA sensing protein kinase R (PKR) (61). eIF2 phosphorylation leads to a reduction in active
ribosomal complexes available for global translation. Among the proteins upregulated by this
mechanism are those involved in certain stress responses (15). Ribosome become more
selective and may preferentially bind one TIS over another stochastically or depending on
sequence context. Neither Tetherin start site is in the context of an optimal Kozak; therefore it is
difficult to predict whether one is preferred over the other. However, viral infection assays in the
presence or absence of PKR should be done to assess whether there are changes in Tetherin
isoform expression. Although none have been seen in human genomic analysis to date, it is
unclear whether there exist naturally occurring polymorphisms around either start site or in the
untranslated region of the human tetherin mRNA that could lead to changes in isoform expression
as is seen in other mammalian species.
Tetherin-Vpu interactions have provided invaluable insight into differential regulation and
function of long and short isoforms.in the context of viral infection. There is clear evidence that
certain viruses do not discriminate between various isoforms. Host-pathogen co-evolution would
suggest that successful viruses could take advantage of Tetherin function to facilitate
transmission. Interestingly, challenge with FIV, which utilizes its Env to counter Tetherin function,
indiscriminately antagonizes both feline Tetherin isoforms, similar to what we have observed with
EBOV GP. Recently, FIV has been suggested to replicate better in felid Tetherin expressing cells.
The existence of a potent short isoform may be a critical barrier against certain viruses that
encode antagonists that do not target the cytoplasmic tail. However, the diversity in mechanisms
by which viruses counter Tetherin function may speak more about how viruses may take
advantage of a particular feature of Tetherin biology for replication. This has been suggested from
observations that Tetherin could facilitate infection (50, 89, 96, 236). Because of differences in
surface stability we would hypothesize that Tetherin isoforms could differentially allow for cell-cell
spread of certain viruses at virological synapses as observed with HTLV-1 and HIV-1.
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Various poorly characterized aspects of Tetherin biology (see Chapter 1) could be
elucidated by studying the impact of l-Tetherin or s-Tetherin in isolation. Stable cell lines encoding
either isoform should be employed to assess potential differential roles of the Tetherin isoforms
from various species in cell-cell spread, NK mediated killing and IFN regulation of
immunoglobulin-like transcript 7 (ILT7), as all three would require single round infection with virus
followed by co-incubation with target cells. We hypothesize that surface stability of s-Tetherin
could be a double-edged sword, potentially enhancing cell-cell transmission of tethered viruses
as previously described (50, 89, 96), but also aiding in antibody-dependent cell-mediated
cytotoxicity (ADCC) (1, 8) by stabilizing antigen (viral particles) on the cell surface. ILT7 on
human pDCs negatively regulates pDC-mediated IFN expression upon interaction with Tetherin
on the surface of IFN stimulated cells. Recently, tethered viral particles were shown to occlude
Tetherin-ILT7 interactions.

By increasing viral tethering on the cell surface, s-Tetherin could

potentially interfere with IFNα dampening in pDCs. In this scenario, one would hypothesize that
the short isoform might aid in viral clearance by maintaining elevated IFN levels. Prolonged
production, however, could have pathological consequences due to prolonged exposure. To date
we do not have evidence of individual human Tetherin isoforms being expressed. However, we
can take advantage of in vitro systems and murine isoform models to assess various isoform
functions and elucidate more of the biology underlying this unique membrane anchored protein.

Summary and perspectives on Tetherin-mediated activation of NF-κB
Our work studying human Tetherin isoforms identified that a previously uncharacterized
NF-κB signaling function is specific to l-Tetherin and that this function is regulated by the
signaling-null s-Tetherin isoform (141), Therefore we initially hypothesized that the necessary
signaling determinants would localize to first 12 amino acids of the Tetherin cytoplasmic tail. We,
and others, discovered that the dual-tyrosine trafficking motif was an important determinant of
NF-κB activation (44, 59, 228). Our preliminary rationale was that the tyrosine-based trafficking
motif resembled an ITAM-like sequence therefore potentially serving dual function. A whole cell
phosphotyrosine proteomics analysis demonstrated that Tetherin could be phosphorylated (211).
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In Chapter 3 we continued to build on understanding Tetherin-mediated signaling through
mutational analysis of the Tetherin cytoplasmic tail. Work from the Neil and Guatelli groups,
published during the time we were conducting the studies highlighted in Chapter 3, described
additional structural determinants of Tetherin-mediated signaling. Compilation of these data has
led to the current model signaling model where Tetherin can sense viral assembly and budding
(59, 228). However, our work has yielded some results that do not agree with the current model
of Tetherin-mediated signaling.
We identified a Tetherin mutant (SY Tetherin) that can activate NF-κB independent of the
dual tyrosine motif, which challenges the current model that Tetherin-mediated signaling through
NF-κB occurs via a hemITAM motif. Substitutions at both cytoplasmic tyrosines in combination
with changes in the serine-threonine-serine (STS) region at the amino terminus of the Tetherin
cytoplasmic tail previously described in Chapter 2 to contribute resistant to HIV-1 Vpu, allow
Tetherin to retain signaling function. In Chapter 3 we identify a single alanine substitution
threonine 4, T4A as sufficient to restore signaling function in the dual tyrosine mutant background
mirroring the effect of this mutant upon Vpu resistance. To assess the contribution of additional
individual residues to NF-κB activation, we engineered cytoplasmic tail point mutants in the lTetherin background to assess contributions of additional individual residues. We observed
mutation at tyrosine 6 to alanine, Y6A, abrogated signaling while Y8A had no effect, confirming
what had been seen in the wt Tetherin background (60). Interestingly, in their triple alanine
substitutions, Galao et al. observed signaling function for mutations at residues 4-6 which
includes T4, S5 in combination with the loss of Y6, paralleling what we see with the dual tyrosine
motif mutant (59). Conservative phenylalanine substitutions revealed that Y6F, unlike Y6A, still
retained the ability to activate NF-κB. Though the dual tyrosine mutant FxF had abrogated
signaling, it is unclear whether the overlapping tyrosines are redundant in function. In the case of
trafficking, both must be mutated to produce aberrant localization (140, 181).
We assessed whether additional point mutations could abrogate Tetherin signaling. We
generated various point mutants in the l-Tetehrin background, highlighting individual residues
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across the entire cytoplasmic tail to be important via alanine scanning mutagenesis. Y6 and R19
alone had the most drastic effect, and had also been also observed to be important (60, 191). We
also identified the importance of position 2. We generated two mutations, a conservative A2V and
a charged A2E, ensuring the Kozak context around the putative start codon was not disrupted.
Both mutants failed to signal. A2V, specifically, expressed primarily lower molecular weight
products suggesting stability was an issue. In the context of position 2, N-terminal processing of
the start methionine is common. N-terminal acetylation has been suggested to play a role in
protein stability and localization (10). N-terminal processing predictive software suggests wt
Tetherin and A2E mutant can be potentially be N-acetylated, but not A2V (146). Peptides isolated
from the phosphoproteomics screen also identified the wt cytoplasmic tail peptide as being Nterminally acetylated at A2 (211).
Direct phosphorylation of the Tetherin cytoplasmic tail at both tyrosines has been
observed in peptides isolated from a phosphoproteomics screen (211). There is a correlation
between signaling competent Tetherin and ability to immunoprecipitate with an antiphosphotyrosine (pY) Ab. However, immunoprecipitation (IP) and co-IP data suggesting that
phosphorylation of Tetherin mediates recruitment of Syk via a hemITAM motif does not
necessarily show a direct interaction. To test a direct interaction between Syk and Tetherin,
synthesized Tetherin cytoplasmic tail peptides with phosphotyrosine modifications could be
produced, immobilized and tested by surface plasmon resonance (SPR). Syk specific binding has
been assessed for CLEC-2 by SPR (88). Swapping the Tetherin tyrosine motif into another
hemITAM containing molecule could also be employed test its ability to act as a bona fide
immunotyrosine-based motif. Swapping the entire human Tetherin cytoplasmic tail onto Tetherin
proteins from another species does not activate NF-κB (59), though the scaffold used in the
study was rhesus Tetherin which has a two amino acid deletion in the TM domain identified as a
determinant for signaling (59). It is unclear whether adding the tail to a heterologous protein with
similar properties as Tetherin (e.g. type II TM, dimerizes, localizes to lipid-rafts) could be enough
to confer function. We would predict that if Tetherin is signaling indirectly through Syk, we could
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still use pY Abs to IP our signaling competent SY mutant. This finding would suggest the need for
an adaptor molecule that could bind Tetherin elsewhere on the tail or through a different domain
to activate signaling.
Tetherin was identified as a PRR sensing viral assembly and budding (59, 228).
Determining whether SY can activate signaling by sensing particle release is important to
strengthen our working hypothesis that Tetherin is not directly recruiting Syk via a hemITAM. The
interaction between Tetherin and RICH2 has been shown to be important for signaling through
actin-mediated activation of Src kinases, which are believed to phosphorylate the hemITAM-like
sequence. However, RICH2 can bind non-signaling Tetherin variants such as the dual tyrosine
mutant equally well (60). The only mutant identified to have very poor binding was a mutant at
R19, which we also observed to be signaling deficient. Based on this observation we would
predict that SY would bind RICH2. We have demonstrated that TAK1 can co-IP with the SY
mutant as has been observed with wt Tetherin (59, 228). Additionally, both Src-family and Syk
kinase specific inhibitors dampened SY-induced signaling in a dose dependent manner
suggesting both kinase families are at least indirectly involved in Tetherin mediated NF-κB
activation. Additional perturbation of both pathways using siRNA against Syk and inhibitors
against TAK1 should be done to confirm our observations and strengthen the model that does not
involve a hemITAM.
Additional mutations in the STS region of the cytoplasmic tail of Tetherin suggests
Tetherin phosphorylation could be important for stabilizing a conformational change within
Tetherin rather than directly recruiting Syk. We believe this may be the underlying mechanism
regulating Tetherin mediated signaling. Acidic mutations in the l-Tetherin background abrogate or
significantly impair signaling, with the exception of the tyrosine proximal serine S5, which is
reduced but not to basal levels. This may explain why A2E also decreased signaling. The STS
region is thought to be under selective pressure in primates. Interestingly swapping STS with the
rhesus sequence PIL abrogates signaling. An S5L substitution, which makes the STS region
more like chimp or gorilla Tetherin retains signaling function, and may actually increase activity.
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These two observations, including an apparent S5L enhancement in signaling, were previously
made in the wt background (157). To our surprise, introducing S5L into the dual-tyrosine motif
mutant restores signaling. Leucine hydrophobicity may be playing a role. Additionally, a series of
polyalanine mutations can be engineered across the entire l-Tetherin specific region of the tail,
still allowing l-Tetherin to retain transient signaling function. Taken together, neutrally charged,
hydrophobic mutations upstream of the dual-tyrosine motif, but not charged or structure altering in
the case of proline from PIL allow Tetherin to signal, suggesting an important and
uncharacterized regulatory function for this STS region.
Phosphorylation of the tyrosine residues in the wt Tetherin cytoplasmic tail could lead to a
conformational change(s) rather than direct recruitment of Syk kinase (Figure 5-2). The various
tyrosine independent, signaling-competent mutants described in Chapter 3 may be primed in a
conformation that facilitates NF-κB activation, mimicking what is observed during wt Tetherin
signaling. We observe that SY Tetherin constantly induces higher levels of NF-κB activation
compared to the l-Tetherin parent. We speculate that a primed Tetherin could access signaling
machinery faster without the need of an activation event, like phosphorylation for example.
However, we do know that SY signaling can be regulated and does not have a dominant
phenotype, at least in the presence of s-Tetherin, as seen in the titration experiments and with
expression of SY in the wt background. The main difference between l- and s-Tetherin is the
length of the cytoplasmic tail. Interaction between the juxtaposed tails of Tetherin isoform
heterodimers (or tetramers) expressed on the cell surface could be important to signaling. One
possible conformational change is enhanced dimerization of the tails, due to a more coiled and
hydrophobic amino identity as a result of the substitutions. In the hemITAM model, Syk kinase
could be doing the same thing if we are to believe it is functioning as Syk has been suggested to
do with CLEC-2 (87). The SH2 domain of Syk or some other SH2 domain containing kinase could
bridge phosphotryrosine residues from adjacent tails bringing the two together. Though our drug
data suggests Syk is still being recruited by some indirect means, this does not rule out the
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possibility that another unknown kinase like PI3 kinase, which has been proposed to interact with
hemITAM motifs and regulate downstream Syk function, could be involved upstream (135).
Enhanced membrane recruitment of the Tetherin cytoplasmic tail could be a possible
mechanism since hydrophobicity has been shown to be important. A recent report described
naturally occurring equine Tetherin proteins that activate NF-κB

in a tyrosine-independent

manner (259). Interestingly, these Tetherins have very short cytoplasmic tails, comparable in
length to s-Tetherin. How do these Tetherins activate signaling in the absence of signaling motif?
A simple explanation could be that there is an unidentified motif present. Alternatively, signaling
observed by equine Tetherin is occurring through an alternative mechanism compared to human
Tetherin. Horse and donkey Tetherin both have a glycine present at position 2 which may
suggest the possibility of these equine Tetherin could be lipidated. Addition of a lipid modification,
like myristoylation, onto these short Tetherin species could enhance membrane targeting. The
myristoylation signal sequence is not optimal compared to the consensus, though there are
examples of myrisoylated proteins that have non-consensus signal sequences.
Tetherin has a membrane proximal basic residue, which could stabilize membrane
interactions with the negatively charged heads on plasma membrane lipids localized to the inner
leaflet (Figure 5-2B, C). R19 mutants abrogate signaling, and additional single alanine scanning
in that region suggests the lysines in the KRCK membrane proximal region could also play a role.
Increased hydrophobicity observed in our tyrosine-independent mutants may target the human
Tetherin cytoplasmic tail to the inner leaflet of the plasma membrane similar a lipid moiety (Figure
5-2C).

Acidic residue introduced in this region could repel those interactions explaining why we

did not observe activation. Secondary structure analysis using predictive software suggests turnlike structure was identified around Y6 using NetTurnP predictive software (173). Secondary
structure predictor suggests coil structures at both ends of the tail (Figure 5-1). (174), The region
in between is predicted to be less structured extended strand (63). The coiled nature increases
with increasing alanine mutations correlating with signaling function. This leads us to predict that
the Tetherin cytoplasmic tail may exist in an inactive state associated with RICH2. Upon
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phosphorylation Tetherin may undergo a conformational change (and possibly additional
modifications), which could mediate membrane targeting. Biophysical assays could provide
insight in determining the dynamics of the Tetherin cytoplasmic tail during signaling as well as the
extent of membrane interactions. Additionally, assessing membrane insertion of SY and
polyalanine Tetherin tails into artificial membranes could suggest membrane interaction in vivo.
As stated earlier, signaling machinery could potentially bind Tetherin on some other part
of the protein, including the second half of the cytoplasmic tail, the TM domain or the GPIanchored end as possible candidates for mediating signaling. GPI-anchored proteins, which don’t
access the cytoplasm, have been demonstrated to signal in various immune contexts primarily in
lymphocytes (213). The role of the Tetherin GPI-anchored has been debated (25, 60, 228).
Billcliff et al. have discussed Tetherin within the context of the “picket fence” model of membrane
organization (25). The “picket fence” model suggests Tetherin can organize these microdomains
and upon clustering can coalesce domains, which increases the size and density of the raft
domains (Figure 1-3B). A recent publication suggests the outer membrane actually exists in a
uniform fluid state and that GPI anchored proteins play a role in limiting lateral diffusion through
steric hindrance (199) and thus could maintain the integrity of protein composition in we describe
as microdomains. Tetherin, which sits both in and out of raft domains via a GPI anchor and
transmembrane domain, respectively, possess this trait as knocking down Tetherin expression
has been associated with increased diffusion of proteins and disruption of the underlying actin
cytoskeletal network ((25, 180). Rafts are known to be sites of signaling platforms, and Tetherin
could be involved in increasing the density to where it and viruses localize when egressing. We
propose that SY could potentially bring microdomains into closer proximity while also stabilizing of
signaling platforms (Figure 5-2D).
Tetherin-mediated signaling has many implications, not only during viral replication, but
also potentially for normal and dysregulated cell biology. Tetherin signaling in cell culture has
been a useful tool to elucidate mechanism, however the consequences of Tetherin mediated
activation in vivo are not clear. Tetherin can enhance immune responses in mice (122). However,
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whether this function is dependent on Tetherin-mediated activation of NF-κB

is unclear. To

assess the role of Tetherin-mediated signaling in vivo, a humanized mouse model would need to
be developed. Tetherin knockout mice have been generated without gross developmental effects
(124, 223). However, in cell culture, murine Tetherin does not activate NF-κB, a caveat being that
the experiments were performed in human cells. The NF-κB pathway is well conserved which
suggests murine Tetherin lacks this function. Identifying whether signaling function is conserved
among different Tetherins in their cognate cells would be important to translate cell culture
systems into animal models.
Another aspect of Tetherin signaling that is unclear is how similar are the three methods
utilized to asses NF-κB activation. Parallel profiles of cytokines have not been assessed.
Transient expression has served as a good tool to streamline various mutants, while crosslinking
facilitates kinetic studies. We currently assume particle tethering, crosslinking, and transient
overexpression via transfection are initiating NF-κB activation via the same mechanism. Tetherin
appears to sense budding particles, but in the absence of viral replication, could this property also
be useful during normal cell biology. Tetherin has been suggested to be upregulated in various
malignant and invasive cell types, though it is unclear what role Tetherin may play. NF-κB
dysregulation has been attributed to various types of cancers and it is tempting to speculate
Tetherin signaling could be somehow be contributing to cell survival, growth and invasion.
Assessing the growth and metastatic nature of cancer cells in the presence and absence of
Tetherin could provide some insight. Taken together, there are still pertinent questions about,
mechanistically, how Tetherin is signaling, as well as what are the implications of this function.
We believe much of the machinery that has been implicated plays an important role, but our
findings suggest signaling may be more nuanced then previously thought.
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Figure 5-1. Compilation of secondary structure analysis of Tetherin cytoplasmic tail.
Alignment of Tetherin sequences for representative mutants from Chapter 4 mutational analysis.
Predictive secondary structure for cytoplasmic tail denoted under sequence. Length of predictive
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Figure 5-2. Our proposed model for Tetherin-mediated signaling. Tetherin exists as a dimer
on the cell surface. (A) The cytoplasmic tails are in a “closed” conformation, preventing signaling
machinery from engaging. (B) The open conformation may bind signaling machinery directly,
downstream of the dual-tyrosine motif. Tyrosine phosphorylation is likely involved in generating
this active state. This interaction may be sufficient to propagate signaling (C) Positive residues in
the tail that are membrane proximal could facilitate interactions with the negatively charged inner
leaflet of the membrane allowing close proximity with machinery that reside in lipid rafts (D)
Alternatively, the Tetherin tail may insert into the membrane allowing Tetherin inhabited
microdomains to come in close proximity (arrow), brining signaling machinery together indirectly
to initiate signaling
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APPENDIX- LIST OF ABBREVIATIONS
Ab –antibody
APC- antigen presentation cell
EBOV – ebolavirus
ER – endoplasmic reticulum
ESCRT – endosomal sorting complexes required for transport
Env – envelope glycoprotein
GP - glycoprotein
GPI anchor – glycophosphatidylinositol anchor
HIV-1 – human Immunodeficiency virus 1
IFN – interferon
IP - immunoprecipitation
IRF – interferon regulatory factor
ISG – IFN stimulated gene
ITAM – immunotyrosine-based activation motif
JAK/STAT - Janus kinase/signal transducer and activator of transcription
l-domain – late budding domain
MVBs – multivesicular bodies
NF-κB – nuclear factor kappa-light chain-enhancer of activated B cells
ORF – open reading frame
PM – plasma membrane
PRR – pattern recognition receptor
RLRs – RIG-I-like receptors
SIV – simian immunodeficiency virus
TGN – trans-Golgi network
TIS – translation initiation site
TLR(s) – Toll-like receptor(s)
TM – transmembrane
VLP(s) – virus-like particle(s)
Vpu – viral protein U
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